Podcasts about Newcastle University

Professor Dame Pamela Shaw is a pioneering Neurologists and a leading figure in tackling motor neurone disease or MND. She is the founder and Director of SITran – the World leading Sheffield Institute for Translational Neuroscience, which is slowly but surely unlocking the secrets of MND and other devastating neurological conditions. Pam was born in Rothbury, Northumberland, in 1955, and at three moved to Kuwait when her father took up the position of harbour master. She lived there until she was eleven, but with no suitable secondary school available locally, she was sent back to Northumberland to board at Our Lady's Convent High School in Alnwick. She studied medicine at Newcastle University and began her clinical training in the North-east. Following her appointment as a consultant neurologist she developed an interest in Motor Neurone Disease. A chance meeting with a recently dignosed MND patient led to Pam founding the Sheffield Institute for Translational Neuroscience in 2010. She was made a Dame in 2014. Pam lives in Sheffield with her husband Paul. They have a grown-up daughter, Sophie. DISC ONE: Messiah HWV 56, "Hallelujah Chorus". Composed by George Frideric Händel and performed by The London Philharmonic Orchestra, The London Philharmonic Chorus, conducted by Douglas Gamley DISC TWO: Somethin' Stupid - Frank Sinatra / Nancy Sinatra DISC THREE: Both Sides Now - Joni Mitchell DISC FOUR: Clarinet Concerto in A Major, K.622: II. Adagio. Composed by Wolfgang Amadeus Mozart and performed by Thea King (clarinet), English Chamber Orchestra, conducted by Alun Francis DISC FIVE: Sweet and Dandy - Toots and the Maytals DISC SIX: The Marriage of Figaro / "Duettino" Sull 'Aria. Composed by Wolfgang Amadeus Mozart and performed by Edith Mathis, Gundula Janowitz (sopranos) The Orchestra of Deutsche Oper Berlin, conducted by Karl Böhm DISC SEVEN: Ashokan Farewell - The Band of H.M. Royal Marines DISC EIGHT: The Lucky One - Alison Krauss & Union StationBOOK CHOICE: Kristin Hannah Collection LUXURY ITEM: Roses CASTAWAY'S FAVOURITE: Clarinet Concerto in A Major, K.622: II. Adagio. Composed by Wolfgang Amadeus Mozart and performed by Thea King (clarinet), English Chamber Orchestra, conducted by Alun Francis Presenter: Lauren Laverne Producer: Tom Alban Desert Island Discs has cast away many medical scientists over the years, including Stephen Westaby, Professor Dame Lesley Regan and David Nott. You can hear their programmes if you search through BBC Sounds or our own Desert Island Discs website.

Send us a text message and tell us your thoughts.Country music in Jamaica sounds like a contradiction until you hear the connections. We connect the dots between Radio Jamaica Rediffusion, Western films on local screens, farm work migration, and a Caribbean listening culture that never treated genres like sealed boxes. We are joined by Jamal Khadar, writer and host of Reimagining Country, who explains how artists like Jim Reeves and Patsy Cline became part of Jamaican soundtracks, and why the cowboy image traveled so well across the Black Atlantic.We go deeper than influence and ask what listeners recognized in country: rural self-recognition, church-rooted morality, survival stories, heartbreak, and the constant question of home. That recognition shows up in reggae's early formation, in rude boy outlaw symbolism, and later in dancehall's Western references and stage names. We also unpack cover culture as a Jamaican superpower, where a song gets re-voiced, re-scored, and re-felt until it becomes something else entirely, sometimes even pushing back into the global north through collaborations and reinterpretations.The conversation also challenges today's narrow story about who “belongs” in country music. Yes, Black roots matter and contemporary moments like Beyoncé's Cowboy Carter open doors, but Jamaica's long-standing love for classic country complicates the picture in a different way: Black audiences have always had wide tastes, including deep affection for “classic” country often made by white artists. We close by widening the map again to African country histories, showing how radio networks, empire, guitars, and post-independence creativity helped build global country scenes that still thrive.Jamal Khadar is a writer, broadcaster, DJ and a key voice on the global history and resurgence of country music, with by-lines in The Guardian, Bandcamp and The European Review of Books and mentions in publications such as the Swiss-German Newspaper WOZ. He also hosts Reimagining Country on NTS Radio. Jamal has shared his research via talks at Goldsmiths, University of London and Newcastle University; with brands like DAZED and Nii Journal; and album liner notes for Mississippi Records. Born in the UK, raised in the Netherlands, but connected to Nashville, he regularly interviews major country artists on their Amsterdam tour stop. After 15 years in London, he now lives in the Amsterdam, The Netherlands.Support the showConnect with Strictly Facts -  Instagram | Facebook | Twitter | LinkedIn | YouTube | Website Looking to read more about the topics covered in this episode? Subscribe to the newsletter at www.strictlyfactspod.com to get the Strictly Facts Syllabus to your email!Want to Support Strictly Facts?Rate & Leave a Review on your favorite platformShare this episode with someone or online and tag usSend us a DM or voice note to have your thoughts featured on an upcoming episode Donate to help us continue empowering listeners with Caribbean history and educationProduced by Breadfruit Media

In this episode, we discover the use of AI in psychiatry education and whether Colleges, supervisors, and trainees will use it well and safely. Dr Nardine Elzahaby, Professor Andrew Teodorczuk, and Dr Michael Weightman break down what responsible AI use looks like in training, supervision, and assessment, and why the biggest risk is not the technology itself, but using it to bypass thinking.Dr Nardine Elzahaby is a Consultation-Liaison psychiatrist and the unit Director of the Adult Mental Health Service at Dandenong hospital, Monash Health. She runs a Telehealth Psychiatry clinic. She is a former co-founder, co-director and tutor at IMGSOS, an online tutoring business for IMG and local graduates of medicine, pharmacy and dentistry. She is interested in Telehealth implementation and the use of AI in psychiatry, business, mentoring and doctors' health. Professor Andrew Teodorczuk is a consultant old age psychiatrist at The Prince Charles Hospital (TPCH) in Brisbane, holding adjunct professor positions at the University of Queensland (UQ) and Queensland University of Technology. Currently President of the Australasian Delirium Association, Prof Teodorczuk joined the RANZCP as Executive Dean of Education in February 2026. Raised in the UK, Professor Teodorczuk was an honorary senior lecturer at Newcastle University and consultant psychiatrist at Northumberland, Tyne and Wear NHS Mental Health Trust. In Australia since 2016, he has held senior leadership roles including Deputy Head of School (Learning and Teaching) at the School of Medicine, Griffith University, MD Program Convenor at the Medical School, UQ and Director Medical Education at Metro North Mental Health. As Director of Clinical Training for PCH he implemented the new AMC National Framework for Prevocational medical training. Publishing over 120 peer-reviewed publications, Professor Teodorczuk has received numerous teaching and research awards. Dr Michael Weightman is a consultant psychiatrist with the Eastern Community Mental Health Service in Adelaide. He also works part-time as a lecturer with the Discipline of Psychiatry at Adelaide University in a role supporting clinical placements and student assessment. Michael is currently undertaking a PhD investigating the impact of AI on psychiatry education and training. Topic suggestion:If you have a topic suggestion or would like to participate in a future episode of Psych Matters, we'd love to hear from you.Please contact us by email at: psychmatters.feedback@ranzcp.orgDisclaimer:This podcast is provided to you for information purposes only and to provide a broad public understanding of various mental health topics.  The podcast may represent the views of the author and not necessarily the views of The Royal Australian and New Zealand College of Psychiatrists ('RANZCP'). The podcast is not to be relied upon as medical advice, or as a substitute for medical advice, does not establish a doctor-patient relationship and should not be a substitute for individual clinical judgement.  By accessing The RANZCP's podcasts you also agree to the full terms and conditions of the RANZCP's Website. Expert mental health information and finding a psychiatrist in Australia or New Zealand is available on the RANZCP's Your Health In Mind Website.

Stuart Bailey is the Head of Payments Industry and Regulation at Lloyds Banking Group, one of the UK's largest and most influential financial institutions. With decades of experience across transaction banking, corporate payments, financial institutions, and regulatory strategy, he has built a career at the heart of how money moves. Stuart plays a leading role in shaping the UK's payments landscape, engaging with regulators, industry bodies, and global networks to drive better outcomes for customers and businesses alike. He is a recognised voice on cross-border payments, digital strategy, and the future of financial infrastructure, regularly speaking at major industry events like SIBOS and the Payments Leaders Summit. Beyond banking, Stuart champions enterprise and entrepreneurship at Newcastle University, personally mentoring student founders and helping build programmes that turn ideas into real businesses. He is someone who has spent his career inside one of the world's biggest financial systems, and somehow still believes it can be changed from within.On The Menu:Why cross-border payments still lose money in transit today Who's liable when an AI makes a bad payment How verification of payee quietly stopped fraud at scale What entrepreneurship at Newcastle University taught him How banks build trust customers don't even notice The four-part Swift scheme fixing international payments Can a giant institution like Lloyds still move fast

After a summer that has seen England and Wales experience the driest July since records began, rain is finally on the horizon. But with reservoirs at ‘exceptionally low' levels, will there be enough rain to replenish stocks? Madeleine Finlay hears from Dr Anna Murgatroyd, a lecturer in hydrology at Newcastle University, about how much rain we need to see us through next summer, why we're now at increased risk of floods, and what we can all be doing to take better care of our water supplies. Help support our independent journalism at theguardian.com/sciencepod

Madeleine Finlay travels to the Rothbury estate in Northumberland, in north-east England. It's a piece of land that has been in the same family for 700 years, but now it has been put up for sale and the UK's Wildlife Trusts are trying to raise £30m to secure it intact. To find out what makes the area so special, Madeleine speaks to Katy Barke, the head of nature recovery for Northumberland Wildlife Trust. She also hears from Sam Turner, a professor of archaeology at Newcastle University, who is trying to work out how the land has been used across the centuries. This work will inform the strategy for nature recovery on the site. And Rosie Pearce, a farm liaison officer, explains how the project could bring more wildlife-friendly farming practices to the estate. Help support our independent journalism at theguardian.com/sciencepod

Back in 2015, 10,000 participants at Newcastle University's Numbers Festival were asked what their favourite number was. Perhaps unsurprisingly, 12.6% of them answered the number seven, making it the most popular number of them all. Some said they didn't know why they chose seven, but as you know, the number tends to have positive connotations and is associated with luck in particular. That's especially true in Western societies. How far back does the legend of lucky number seven go? How has the concept of luck contributed to the number seven's prominence? Are there any scientific or logical reasons behind the number seven's lucky reputation? In under 3 minutes, we answer your questions! To listen to the last episodes, you can click here : ⁠Why is the celibacy movement attracting young people?⁠ ⁠What is a faecal transplant?⁠ ⁠How can I relax my brain while on holiday?⁠ A podcast written and realised by Joseph Chance. First broadcast: 14/08/2023 Learn more about your ad choices. Visit megaphone.fm/adchoices

Anne-Marie Lacey is a multi-award-winning Chartered PR practitioner, strategic adviser and Senior Lecturer at Newcastle University. She combines real-world experience with evidence-based thinking to develop strategic communicators and strengthen the profession. Her career spans agency, consultancy, in-house advisory and higher education, having worked with organisations in the lifestyle, leisure and entertainment sectors, including some of the world's best-known brands. A CIPR Fellow and recipient of the Sir Stephen Tallents Medal, Anne-Marie has lived the membership journey, spending almost 15 years volunteering across the Institute, from Student Representative to Board Director. Those experiences have given her a unique perspective on the strengths of the Institute and the opportunities to do even more for members. The news was announced this week that she's currently standing for CIPR President-Elect 2027. I've known her for nearly a decade and wanted to give my listeners a chance to find out more about the news and her reasons for putting her hat in the ring. Listen to discover: why she's decided to put herself forward now the role of belonging and relevancy within membership associations her strong views on lobbying and why share of voice and representation matters Thank you for tuning in. Rachel Show notes can be found at allthingsic.com/podcast

Today, a major incident has been declared in Suffolk where a wildfire the size of 140 football pitches is burning. The fire is not yet under control, but Suffolk's chief fire officer says it currently poses no risk to nearby nuclear power station Sizewell B. And, in the rest of the UK, drought has been declared in Wales and more than half of England.Adam is joined by Anna Murgatroyd, lecturer in hydrology at Newcastle University, and Theodore Keeping, climate and wildfire scientist at Imperial College London, to discuss how the fire service are tackling the blaze plus how daily life could be affected by a drought in England and Wales.And, the conflict between the US and Iran has expanded following escalations over the last few weeks. The US has retaliated with strikes across the country after Iran launched attacks on US bases in Jordan earlier this week. Caitríona Perry, chief news presenter, and Parham Ghobadi, senior reporter for BBC Persian, join Adam to explain the latest developments in the conflict. You can now listen to Newscast on a smart speaker. If you want to listen, just say "Ask BBC Sounds to play Newscast”. It works on most smart speakers. You can join our Newscast online community here: https://bbc.in/newscastdiscordGet in touch with Newscast by emailing newscast@bbc.co.uk or send us a WhatsApp on +44 0330 123 9480.New episodes released every day. If you're in the UK, for more News and Current Affairs podcasts from the BBC, listen on BBC Sounds: https://bbc.in/4guXgXd Newscast brings you daily analysis of the latest political news stories from the BBC. The presenter was Adam Fleming. It was made by Jack Maclaren with Anna Harris and Rosie Merotra. The social producer was Gabriel Purcell-Davis and Beth Pritchard. The technical producer was Dafydd Evans. The assistant editor is Chris Gray. The senior news editor is Sam Bonham.

In this episode, we are exploring innovative research methodologies in genetics, including narrative and visual methods, conversation analysis and body mapping. Our guests highlight using these methods to drive inclusive and diverse research as well as providing a more nuanced understanding of the lived experiences of families.    Segment 1: Defining joy after a genetic diagnosis: A narrative inquiry   Guest Bio: UNC Greensboro Genetic Counseling Program graduate Jordan Miller earned a masters degree in genetic counseling in 2025 and currently works as a prenatal and cancer genetic counselor at Prisma Health in Columbia, South Carolina. In addition to clinical practice, Jordan serves as part of the faculty for the University of South Carolina Genetic Counseling program, where she is passionate about supporting and mentoring future genetic counselors.   Following a personal experience of finding joy after a devastating family diagnosis, Jordan developed a deep passion for exploring how joy, hope, and humanity can remain central to patient care. Her work and advocacy focus on fostering meaningful conversations about compassionate care and the ways healthcare professionals can help patients and families find moments of connection and resilience during difficult experiences.   In this segment we discuss: - The use of qualitative narrative inquiry and in-person observations, rather than standard surveys, to capture the visceral, underreported experience of joy following a family genetic diagnosis. - The "FERN" grounded framework (Focusing on the present, Embracing life, Redefining joy, and Normalizing the journey) and how its core themes emerged from family narratives. - How healthcare providers and communities can foster joy and humanize care by interacting with pediatric patients as individuals rather than focusing solely on their diagnosis. - Balancing grief and joy in healthcare conversations without pushing toxic positivity, highlighting how small daily moments of joy help families hold onto hope.   Segment 2: Expanding the methodological repertoire: Integrating multimodal approaches in genetic counseling research   Guest Bios: Ms Malebo Malope is a clinical genetic counsellor and currently employed at Stellenbosch University as a lecturer. She coordinates the teaching activities for the Clinical Genetics and Genetic Counselling Unit and leads short courses within the unit. Additionally, Malebo provides clinical genetic counselling at Tygerberg Hospital and participates in clinical training.  Ms Malope has a special interest in decision-making on termination of pregnancy for foetal abnormalities, accessible genetic counselling services and diversity and inclusion within the field of genetics and genomics.   Dr Megan Scott is a South African clinical genetic counsellor and health communication researcher based in Johannesburg. She holds a PhD in Health Communication and works in independent clinical practice, supporting individuals and families across a wide range of genetic indications, including prenatal, paediatric, oncology, ophthalmology and psychiatric genetics. She is actively involved in the South African medical genetics community, including student supervision and training and has previously served on the Genetic Counsellors South Africa (GCSA) committee. Dr Scott is also a Research Associate at the Health Communication Research Unit (HCRU) at the University of the Witwatersrand. Her research focuses on improving healthcare practice across interdisciplinary fields, qualitative research methods, risk and uncertainty discussions, family communication and patient-centred care. She has presented at local and international conferences, published in the fields of genetic counselling and health communication and regularly reviews for academic journals. She also serves as a supervisor, reviewer and examiner for postgraduate students in genetic counselling, public health, psychology and clinical medicine.   Dr Lorraine Cowley is a clinical academic with a background in oncology nursing and currently serves as Principal Genetic Counsellor at the Northern Genetics Service, Newcastle upon Tyne Hospitals NHS Foundation Trust. She is also an Honorary Senior Lecturer at Newcastle University. With over 25 years of experience in patient perspectives research, Lorraine has led, co-led, supervised and contributed to numerous national and international studies, with a particular focus on improving patient-centred approaches in genetic and rare disease services. She is currently funded by the Medical Research Council (MRC) and the National Institute for Health and Social Care Research (NIHR) through a Clinical Academic Research Partnership (CARP) Fellowship. Her current work involves collaboration across Latin America and the UK to evaluate the delivery and impact of whole exome sequencing for individuals with rare muscle disorders, aiming to improve equitable access to genomic diagnostics in rare disease care.   In this segment we discuss: - How visual methods like photographic elicitation and social mapping challenge traditional biological pedigrees, revealing diverse family dynamics, gendered support roles, and moral tensions around genetic testing. - The therapeutic and harm-reduction benefits of body mapping in complex pregnancy cases, allowing patients to express embodied emotional experiences beyond verbal language. - Applying conversation analysis to real-time clinical consultations to observe non-verbal cues and explore the complex tension between counselor neutrality and institutional expectations. - The potential of multimodal methodologies to capture culturally specific kinship structures globally and their application as reflective tools in genetic counseling supervision and training.   Would you like to nominate a JoGC article to be featured in the show? If so, please fill out this nomination submission form here. Multiple entries are encouraged including articles where you, your colleagues, or your friends are authors.   Stay tuned for the next new episode of DNA Dialogues! In the meantime, listen to all our episodes Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Dialogues”.    For more information about this episode visit dnadialogues.podbean.com, where you can also stream all episodes of the show. Check out the Journal of Genetic Counseling here for articles featured in this episode and others.    Any questions, episode ideas, guest pitches, or comments can be sent into DNADialoguesPodcast@gmail.com.    DNA Dialogues' team includes Jehannine Austin, Naomi Wagner, Khalida Liaquat, Kate Wilson and DNA Today's Kira Dineen. Our logo was designed by Ashlyn Enokian. Our current intern is Vanaja Chaava.

An extra half hour of The Panel with Wallace Chapman, where to begin, he's joined by Nights host Emile Donovan. Then: Andy Burnham has been in the job of the UK Prime Minister for one week. What have we learned? Martin Far, Senior Lecturer in Contemporary British History at Newcastle University discusses what the new PM went and what's to come.

Plant trees down high streets. Retrofit schools, hospitals and care homes with external shading. Cool down beds and install ceiling fans. Legislate for minimum indoor temperatures. Ban glass towers. Paint roofs white. Set up a cooling refuge in every community. Reduce glazing and install windows that open. These are just some of the measures discussed by our panel of leading experts on climate and the built environment in this month's 21CC podcast, convened to brainstorm what we can do, starting right now, to make towns and cities safe and liveable even as the long-predicted, human-caused warming intensifies. Chairing this brisk and purposeful discussion is Saul Humphrey FCIOB, this year's president of the Chartered Institute of Building: an industry veteran and professor of sustainable construction management at Anglia Ruskin University. Giving us their insights are: Dr Arash Beizaee, senior lecturer in building energy at Loughborough University, an expert on thermal comfort, overheating and health in buildings who is developing practical, low-energy interventions to safeguard wellbeing; Dr Macarena Cardenas, senior advisor for resilience and nature at the UK Green Building Council and leader of industry-scale programmes across the built environment; Dr Hayley Fowler, professor of climate change impacts at Newcastle University and recipient of a Royal Society Faraday Discovery Fellowship for her Extreme Futures project improving how we forecast flash floods and prolonged storms more accurately; Dr Susan Roaf, emeritus professor of architectural engineering at Heriot Watt University and co-author of Adaptive Thermal Comfort: At the Extremes (Routledge, 2026), which calls for a revolution among building designers, owners, managers, and occupants to prepare for the future that is upon us; Jordan Turner, senior lecturer at the University of the Built Environment. The future is here; there's no time to lose.

If you own a brewery, where did you source your brewhouse from? It might have come from one of the leading manufacturers and suppliers in the industry. Or perhaps it was a piece of loved, second-hand kit that needed a new home. You were unlikely, however, to have been chased around the streets of Vienna by an angry auctioneer looking for their money. But that's exactly what happened, through no fault of his own, to Reece Hugill. And thankfully the whole saga would result in the creation of one of the UK's finest breweries. In an industry often seduced by the pressure of relentless expansion, multi-site taprooms, and national supermarket listings, Reece Hugill has chosen a radically different path. As the founder behind Donzoko Brewing Company, he has built something that craft beer frequently preaches but rarely delivers: a fierce, uncompromising sense of place. In this episode of The Brewers Journal Podcast, we sit down with Reece to trace the winding, highly entertaining, and deeply passionate story of Donzoko. It is a journey that began when a Newcastle University chemistry student realised that brewing lager in a friend's school kitchen during a study abroad year was far more soul-fulfilling than a life in the lab. After brewing stints in Edinburgh and navigating the uncertainties of the pandemic, Reece reached a critical turning point. Taking direct inspiration from the rustic Kellers and village brewpubs of Franconia, he brought Donzoko back to its emotional home in Newcastle upon Tyne, establishing a 10-hectolitre brewpub and taproom just around the corner from where his first beers were poured. Reece also shares his candid thoughts on why beer culture suffers when every brand is available everywhere, why true passion trumps rigid textbook numbers, and why creating a hyper-local hub for his community is the ultimate reward.

Vous pensez ne plus avoir besoin de vitamine D dès que les beaux jours reviennent ? C'est aussi ce que je pensais : j'avais arrêté ma supplémentation en juin, rassuré par mes bons niveaux du printemps. Puis une discussion avec ma nutritionniste et une étude qui a fait du bruit ont semé le doute. Dans cet épisode, je décortique ce que disent vraiment les études sur la synthèse de la vitamine D et je vous donne les clés pour savoir si votre mode de vie remplit réellement les conditions pour en fabriquer suffisamment, même en plein été.Liens complémentairesGratuit : Le kit Reboot pour retrouver la forme et l'énergie avec la méthode SAMi et des outils : https://sn.soulier.xyz/kitLe Protocole Perte de Gras : https://go.soulier.xyz/protocolesnLa Stratégie FlowFit pour bouger et plus et prendre du muscle (tarif de lancement spécial) : https://go.soulier.xyz/flowfitsnComposez vos salades protéinées en quelques secondes avec l'assistant Salade Express : https://go.soulier.xyz/saladesnTous les liens complémentaires et anciens épisodes : https://sn.soulier.xyz/191Nutripure : https://go.soulier.xyz/NutripureSN. Profitez de 10% de réduction sur votre première commande avec le code HAMSTERSRejoindre le Hamsters Running Club : https://sn.soulier.xyz/hrcEn mars, mes analyses de sang montraient des niveaux de vitamine D très corrects. C'était le résultat de la combinaison d'une bonne alimentation, de sorties régulières et d'une supplémentation hivernale. Logiquement, avec l'arrivée des beaux jours, j'ai arrêté ma cure : plus de soleil, plus de luminosité, donc plus besoin, non ?C'est ce que beaucoup d'entre nous pensent. Mais une conversation avec ma nutritionniste m'a fait douter, et une étude récente de la Newcastle University (publiée en juin 2026 dans l'European Journal of Clinical Nutrition) est venue confirmer ce doute : chez les participants suivis, les niveaux de vitamine D ne remontaient pas l'été, alors même que la logique voudrait l'inverse.Avant de généraliser, j'ai voulu vérifier les biais possibles de cette étude (financement, population étudiée, latitude) et surtout comprendre ce que la science dit vraiment des conditions de synthèse cutanée de la vitamine D : quelle heure de la journée compte, quelle surface de peau exposée, quel rôle joue la crème solaire, l'âge, ou un mode de vie sédentaire.En confrontant ces données à mon propre mode de vie (sorties matinales, travail de bureau, peu d'exposition en milieu de journée) j'ai eu une vraie surprise sur ma propre situation.Cet épisode n'est pas un raccourci du type "prenez de la vitamine D toute l'année" : c'est une invitation à interroger vos propres habitudes d'exposition au soleil, pour savoir si vous remplissez réellement les conditions pour en synthétiser assez ou si, comme moi, l'été ne change pas grand-chose.Dans cet épisode :Faut-il vraiment arrêter la vitamine D dès que l'été arrive ?Que révèle une étude récente de la Newcastle University sur les niveaux de vitamine D en été ?Quels sont les biais possibles de cette étude à connaître avant d'en tirer des conclusions ?Comment la peau synthétise-t-elle réellement la vitamine D grâce au soleil ?La crème solaire bloque-t-elle vraiment la synthèse de vitamine D ?Quelle heure de la journée est la plus efficace pour synthétiser de la vitamine D ?Quel rôle joue l'âge dans la capacité à produire de la vitamine D ?Un mode de vie sédentaire ou des sorties sportives matinales peuvent-ils suffire à limiter la synthèse malgré le soleil d'été ?Nouveau : Le protocole Perte de Gras 2025 ❤️ Me suivre Tous les liens sont ici

In this episode of The Dairy Podcast Show, Holly Malins, Ruminant Business Manager at Evonik Animal Nutrition, explains how capsaicin compounds from chili peppers can support dairy cow performance. She explores its effects on digestion, nutrient absorption, and glucose use, especially during early lactation and heat stress. Get practical insights that highlight consistency, application, and production responses. Listen now on all major platforms!"Capsaicinoids act as bioactive compounds that influence digestion and metabolism through receptor activation within the gastrointestinal tract."Meet the guest: Holly Malins earned a degree in Agriculture from Newcastle University and a Master's in Applied Poultry Science from the University of Glasgow. At Evonik Animal Nutrition, she focuses on ruminant nutrition, emphasizing amino acids and innovative feed solutions to improve dairy cow performance across Europe. Learn more about capsaicin strategies with Holly Malins on The Dairy Podcast Show, available on all major platforms.Liked this one? Don't stop now — Here's what we think you'll love!Tales Lelis: Rumen-Protected Amino Acids | Ep. 70What you'll learn:(00:00) Highlight(01:36) Introduction(04:43) Guest background overview(06:59) Capsaicinoids explained(12:36) Capsaicin function(17:56) Farm applications(24:09) Capsaicin sources availability(24:53) Final questionsThe Dairy Podcast Show is trusted and supported by innovative companies like:* Evonik* Adisseo* CowManager* Afimilk* Agri-Comfort- DietForge- AHV- BoviSync- Natural Biologics- dsm-firmenich- Protekta- Agrarian Solutions- Chemlock Nutrition- Rangen Group

This lecture will focus on independently produced Chinese documentary cinema as it has entered the Anglophone industry market. Using “Plastic China” by the award-winning director Wang Jiuliang as a case study, I will explore what the implications of cross-border collaborations are for documentary form and content, and how this may encourage a particular set of viewer responses. This will allow me to locate the documentary form in relation to broader liberal arguments over China's place in the world system and assess the limitations of this approach to “going global” for independent Chinese documentary.This lecture was recorded by Luke Robinson on the 27th of May 2026Luke Robinson is a Senior Lecturer/Associate Professor in Film Studies in the Faculty of Media, Arts, and Humanitiies, University of Sussex.He is the author of Independent Chinese Documentary: From the Studio to the Street, and the co-editor of two further collections on Chinese film culture: (with Chris Berry) Chinese Film Festivals: Sites of Translation and (with Chris Berry, Lydia Wu and Sabrina Yu) Chinese Independent Cinema: Past, Present, and a Questionable Future.His writing has appeared in books and journals including DV-made China, The New Chinese Documentary Movement, Vocal Projections, Screening China's Soft Power, positions: Asia cultures critique, Film Studies, Screen, and Journal of Chinese Cinemas.Between 2019 and 2025 he was co-investigator on the AHRC-funded project, “Independent Cinema in China: State, Market, and Film Culture”. One of the outcomes of this grant was the establishment of the Chinese Independent Film Archive, located at Newcastle University.The transcript of the lecture is available from the Gresham College website: https://www.gresham.ac.uk/watch-now/chinese-documentaryGresham College has offered free public lectures for over 400 years, thanks to the generosity of our supporters. There are currently over 2,500 lectures free to access. We believe that everyone should have the opportunity to learn from some of the greatest minds. To support Gresham College's mission, please consider making a donation: https://www.gresham.ac.uk/get-involved/support-us/make-donation/donate-today Website:  https://gresham.ac.ukX: https://x.com/GreshamCollegeFacebook: https://facebook.com/greshamcollegeInstagram: https://instagram.com/greshamcollegeBluesky: https://bsky.app/profile/greshamcollege.bsky.social TikTok: https://www.tiktok.com/@greshamcollegeSupport Us: https://www.gresham.ac.uk/get-involved/support-us/make-donation/donate-todaySupport the show

What will a Burnham premiership mean for Wales? Former Labour communications advisor Scarlett MccGwire discusses. With a new party in government, what is the future of transport in Wales? Cardiff University's Mark Barry and the new deputy minister for transport, Mark Hooper are in the studio. We've had the hottest June on record and climate change is getting the blame. Professor Hayley Fowler from Newcastle University tells us why. And it's the 150th anniversary of the battle of Little Big Horn in Montana, USA. Journalist and author Mike Lewis knows about a Welsh connection.Our interviews with new members of the Senedd continue: this week we have one of Plaid Cymru's three Rhondda Cynon Merthyr MSs, Sara Crowley.

Dr. Martin Farr, a senior lecturer in contemporary British history at Newcastle University, joined "Forbes Newsroom" to discuss Prime Minister Keir Starmer's resignation and the impact that his stepping down could have on politics in the United Kingdom. Learn more about your ad choices. Visit megaphone.fm/adchoices

A daily low dose of aspirin could significantly reduce the risk of bowel cancer in people with Lynch syndrome, an inherited condition that increases the likelihood of developing certain cancers.   In this episode, we explore the findings from the landmark CaPP3 trial, hear from a participant living with Lynch syndrome, and discuss how genomics could help shift healthcare from treatment to prevention.  Our host, Sharon Jones is joined by:  Dr Katie Snape, Principal Clinician for Population Health at Genomics England  Professor Sir John Burn, Professor of Clinical Genetics at Newcastle University  Drew Hyde, participant in the Cancer Prevention Programme (CaPP3)  Links:  Listen to: How can genomics help us understand cancer?  "I think knowing is always a good thing. And obviously, I wish I'd known earlier, and then, I could have taken more measures earlier on. So I think knowledge is definitely a good thing. And it would be great if more people could be tested or could find out if they were carriers at an early age, I think."  You can download the transcript or read it below. [00:00:00] Sharon: Welcome to Behind the Genes. In today's episode, we'll explore the research which shows how a low dose of aspirin can halve the risk of bowel cancer in people with Lynch syndrome. We'll hear about the real-life impact of living with the condition, and look at how genomics can help shape a more preventative approach to care in the future. [00:00:20] I'm Sharon Jones, and to help us unpack all of that, I'm joined by our guests, Dr. Katie Snape, principal clinician for population health at Genomics England; Sir John Burn, professor of clinical genetics at Newcastle University; and Drew Hyde, a participant in the Cancer Prevention Programme, which is also known as the CaPP3 trial. [00:00:42] So to start with the basics, Katie, can you walk us through what cancer is in simple terms? [00:00:50] Katie: Sure, Sharon. So, our body is made up of cells. Those are the building blocks that, that make us as humans and other creatures and plants. And our cells need to keep dividing throughout our lifetime as our bodies are growing and working normally. [00:01:06] And so we need to have processes in place in our body where our cells can divide, but then also stop dividing when we don't need them to carry on dividing. What happens in a cancer cell is basically that cell becomes abnormal, and it doesn't follow the normal checks and balances and rules of cell division. [00:01:23] So it starts to divide and grow uncontrollably, and it can start to invade other tissues and obviously, that can cause serious consequences. [00:01:33] Sharon: We'll hear a lot more from Dr. Katie Snape in this episode. But before we move on, I just wanted to flag that there was an episode of our Genomics 101 explainer series with Katie dedicated to helping us get to grips with how genomics can help us understand and diagnose cancer. [00:01:47] Do go and check that out. We'll put a link to that in the episode description. [00:01:54] So the World Health Organization estimates between 30 to 50% of all cancers are preventable. So, Katie, when we talk about cancer being preventable, what does that actually mean? And what's an example of cancer prevention that people might already know? [00:02:11] Katie: Yeah. So some cancers are due to chance or just mistakes happening as our cells copy. [00:02:19] Other cancers are because there has been damage to the genetic information within the cell that can be caused by certain things that can cause damage to DNA. So for example, a sort of obvious answer would be skin cancer. Skin cancers can be caused by sunlight, the, the UV light in the sun, and particularly if we burn our skin or, or get sun damage to our skin, increases the chance of us developing a skin cancer. [00:02:44] So you can think of lots of other examples such as cigarette smoking and lung cancer, and so we know that there are a number of different risk factors that increase the chance of our cells developing damage and becoming abnormal cells and growing uncontrollably. So when we talk about prevention, we might think, well, could we reduce some of those risk factors and therefore reduce the chance of those cells getting damaged and becoming cancer cells? [00:03:10] So I gave the example of skin cancer. We might put sun cream on if we're going out in the midday sun, for example. That reduces the damage of the UV light onto our skin cells. Or we might help people to go into a smoking prevention programme or, you know, other risk factors, such as we know that being very overweight can increase the chance of cancer. [00:03:31] We might help people get into more exercise regimes or improve people's diets. So those are the sorts of things that we might do sort of for environmental risk factors. But we also know, particularly in this context, that sometimes people are born, they carry genetic changes within their cells that they're born with, that are inherited, that run through families, and those can also increase the chance of some cancers developing. [00:03:56] And for those people at higher genetic risk, then we might look to other ways that we might reduce that risk. We can't change the genetic changes in their cells, but we might be able to put things in place to reduce the risk for those individuals, and that might be medication, it might be surgery, or there could be other things that we might be able to offer. [00:04:15] Sharon: Yeah, and with that in mind, is there anything more, you know, that you can share about some of those risk factors that someone is more likely to develop cancer? [00:04:25] Katie: Yeah. So actually, the, the biggest risk factor for developing cancer is age. The older we get, the more times our cells have divided, the more chance there is of a copying mistake that, that, that can cause that cell to become abnormal and start growing uncontrollably. [00:04:41] And that's why cancer becomes more common the older we get. We obviously can't change our aging process. Then, as I've said, sometimes we're born with certain specific inherited factors that increase the risk. That might be one big high-risk genetic factor, such as having a cancer gene that's important for, for that process of cell division that isn't working properly. [00:05:04] Or it could be that we have multiple lower genetic risk factors that can kind of add up together to increase the risk. And those often interplay with some of those environmental factors that we've talked about, like smoking, for example, or weight, or alcohol or other things like that. So most cancers are due to aging, and then there's a sort of interplay of genetic factors, but environmental factors as well. [00:05:30] Sharon: That's really interesting to understand. And the focus of this podcast is sort of looking at kind of Lynch syndrome and what findings have come out around aspirin and having a low dose of aspirin. So I want to kind of explore what Lynch syndrome is and, and then bring in Drew to talk about his experience of having Lynch syndrome and how he got involved in the trials themselves. [00:05:49] So from what I understand, Lynch syndrome is a genetic condition that can make some people more likely to have the chances of developing into bowel cancer. And Drew, this is your opportunity to sort of talk about what that's been like living with Lynch syndrome. And, you know, I'd like to understand more about your story and how it came about that you discovered that you had Lynch syndrome, and to share with our listeners your journey. [00:06:13] Drew: Yep. So in my case, I discovered I had the colon cancer before I discovered I was a Lynch syndrome carrier Basically, at the age of 50, I noticed some change in my health. You know, I was becoming a little bit more tired. My bowel movements had changed or whatever. So, I went to the GP and the GP basically said, "Well, you're probably too young for cancer, so let's look at other alternatives." [00:06:37] And I had blood tests and I had low iron, so I was on iron tablets for three months and whatever. Then eventually I went back and finally the GP said, "Well, let's try a colonoscopy." And the colonoscopy revealed that I did actually have colon cancer. And then very quickly I had surgery and, uh, then following that, I kind of asked the question, "Well, why me?" [00:06:59] You know, I'm only 50, 51. Yeah. You know, why me? [00:07:02] Drew: And basically, I was told, "Well, it's probably genetics." And then I was referred to, you know, St George's and Katie and I had the test and discovered that I was actually a Lynch syndrome carrier, and that's why, you know, I'd got the colon cancer at the age of 50, so. [00:07:17] Sharon: I mean, that's quite a journey. I mean, how did you feel when you're already on one pathway and then having to kind of find out more, you know, what was your experiences? What was the impact on your life? How did you, how did you feel? [00:07:27] Drew: I think I was lucky in that I had a very good surgeon. I had surgery very quickly, so that was the first hurdle. [00:07:32] Then I had to go on to chemotherapy, and the chemotherapy obviously is far worse than any surgery or anything else that comes before or after. But having got through that, then I went through the St George's onto the Lynch syndrome system. So, the most important thing then really was to basically identify what that meant for me, but also because it was an inherited characteristic, what it meant for my family. [00:07:57] One thing that was interesting, and I say, you know, the, the GP was saying, "Well, you're too young to have cancer," is that there wasn't any history of cancer in my family, you know, looking at older relatives. So, you know, to be fair to the GP, that wasn't an obvious marker. So basically, yeah, it was let's, you know, find out what it means now going forward. [00:08:21] Sharon: So, can you just take us back to when you were diagnosed with Lynch syndrome? What sort of guidance were you given at the time about managing your cancer risk? [00:08:30] Drew: Well, following the surgery, I was given various statistics which were fairly grim on what your percentage survival rate were in three years, five years, 10 years based on the surgery, whatever. [00:08:39] And that was kind of a bit harrowing. But, you know, assuming I'd get through five years, I felt it was, my chances were quite good. As for myself living with, living with Lynch syndrome, that, you know, I was aware that having had the colon cancer, I then had increased risk of other cancers. So since then, I've been on a screening programme, and I have colonoscopies or gastroscopies every year or two years. [00:09:04] So that's been very good. So, I believe now that if any other cancers were to appear, I would probably know very early on because they would be detected through a screening process before they got to a point where they would be, you know, maybe too difficult to resolve, so. So that's-- I think the screening programme, has been very, very good. [00:09:23] The main issue for me was what it meant for my family, being a genetic thing. So very quickly, my children, who were teenagers at the time, were both tested, and they went through some counselling with Katie beforehand, you know, about what it would mean for them to get a positive or negative result. [00:09:42] Unfortunately, my daughter was tested as negative, but my son was tested as positive, so he's now on the same cancer screening programme, and has colonoscopies every two years. So yeah. The mystery really, though, is where I inherited it from because my father died when I was very young. My mother was in a care home at the time, and I wanted to get her tested. [00:10:07] And at the time, her GP wouldn't test her on the basis that she was unable to give consent. But fortunately, I had power of attorney, and we could persuade him to do the test. But she tested negative. So I'm assuming I inherited it from my father's side. But most of my grandparents on that side of the family lived into their nineties without any apparent cancers. [00:10:32] So it's still a bit of a mystery how I inherited it, but what was important for me was to know which side of the family I'd inherited it from because obviously with cousins and whatever on different sides of the family, I wanted to be able to tell them what the situation was. My brother also tested negative, which was a positive. [00:10:54] So at the moment, it's just my son and I that have the defective gene. [00:10:59] Sharon: I'm sorry to hear that about your son, but does it- [00:11:01] Drew: Well, well, I mean, he, you know, he has to go through a colonoscopy every couple of years, which, you know, obviously is not a pleasant experience. But at least he knows that, you know, the first sign of any problem, the medics will be aware of it, and he'll be able to react. [00:11:16] Sharon: Has it changed your outlook on life, having this window in possibly knowing stuff or not knowing stuff? How has that affected you and, and your son as well? [00:11:25] Drew: I think knowing is always a good thing. And obviously, I wish I'd known earlier, and then, I could have taken more measures earlier on. So, I think knowledge is definitely a good thing. And it would be great if more people could be tested or could find out if they were carriers at an early age, I think. [00:11:42] Sharon: Yeah. That is really important. And moving into about the trial more broadly, scientists have known that there's been a link between cancer and aspirin for some time, with fewer cancers observed in people who take aspirin. So coming to you, John, could you share a bit more about the history of inherited cancer research and how the focus of Lynch Syndrome came about? [00:12:02] Because this isn't new, is it? [00:12:06] John: No, absolutely, Sharon. And in fact, this story, my story in this space begins 40 years ago when I was one of the geneticists who set out to try and find the genes that we've just been talking about. At that time, the group of patients who were the most obvious to begin with were young people with a condition called familial adenomatous polyposis, or FAP for short. [00:12:26] And they'd get thousands of polyps in their bowel, and the only way to treat that was to actually remove the whole bowel when they reached adulthood, which is a fairly extreme intervention. And I was running, I was setting up a registry. We were trying to find the gene at that time, and we'd just found it, in fact, but we also were trying to find all the families. [00:12:44] And I'd taken over responsibility for all the genetic services in the north of England, in the North East and Cumbria. And we'd, I'd started identifying families with FAP, and we went to visit one of those families, and this was the kind of light bulb moment for me because I walked into the room and mum had had her colon removed, and her son, Jonathan, had just had his first colonoscopy at the age of 12, and it was clear. [00:13:07] And I was about to give them the good news, but as I walked in, I noticed that he had little bumps on his forehead called osteomas, little bony bumps. His mother had them just the same, and it was one of the features of this condition. So I knew he had the gene even though he hadn't yet got the polyps. [00:13:21] Sharon: Wow. [00:13:22] John: And it made me think, wouldn't it be nice if we could do something to prevent these things happening rather than just waiting for an operation? And as it happened at the time, I was leading the English end of a big study, which you'll probably be aware of, which we're, we're, we were doing the vitamin study on women with spina bifida babies, and we were just about to identify folic acid as a way of preventing spina bifida in pregnant women. [00:13:45] So I had these two thoughts in my head. Maybe we could set up a trial like this folic acid trial, and then one of my friends in Edinburgh said, 'Have you seen this paper from Melbourne?' Gabriel Kuhn had just done a big study looking at people with colon cancer. It seemed that people who took a lot of aspirin didn't seem to get as much bowel cancer in Melbourne as those who didn't. So that was the design set up. [00:14:08] We were applying to Europe for a concerted action, so we had to think of an acronym that began with CA. So I, I came up with Concerted Action Polyp Prevention. But then in 1993, just as we started that trial, we were involved in finding the first of the genes for Lynch syndrome. We had a big family in Northumberland where there were lots of people like Drew's family, and there were three generations of cancer in the family. [00:14:31] So CaPP2 was immediately born in my head. In 1999, we had our first recruit, and we recruited until 2005. We found, in total, 1,000 people in 16 countries to join in, and we gave them two aspirins a day or two dummy tablets. Two aspirins is quite a big dose, but back in my day when I was a junior doctor, we used to give many more tablets of aspirin to people with arthritis. [00:14:57] So two tablets wasn't such a big deal. Nowadays, it's seen as a very high dose. And it worked. Basically, to cut to the chase, when we looked in 2010, the people who were getting the aspirin were getting less bowel cancers. In fact, it was a 50% reduction. So the people who took two aspirins had half as many bowel cancers and fewer cancers of other types as well. [00:15:19] We realised, although, at this point, immediately we saw that it was working, we knew we'd need to do another trial to see whether a smaller dose of aspirin would be just as effective. So CaPP3 began, and the great news is that what we'll be reporting in the journals in the next few days when it gets published, is that the people who were taking  CaPP3 aspirin in any dose were tracking exactly the same as the 600-milligram group in CaPP2. [00:15:46] So we're pretty sure that it works. We're pretty sure that the small dose is just as good. And the great news was that we had fewer side effects in that group. And so in fact, no one had to go to hospital for a transfusion or anything, you know, like that. Whereas in the 600-milligram group, we had a few people who needed treatment because, as you know, and everyone knows, if you take aspirin, there's a higher chance of having an ulcer that causes a bleed. [00:16:10] And that was always the anxiety. But people like Drew were courageous enough to take the chance because they knew we needed to know the answer to this. And of course, when you compare it to the risk of getting cancer, taking an aspirin is a relatively small risk. [00:16:26] Sharon: So, what were your kind of considerations when you were designing the trial, having that knowledge? [00:16:32] John: Well, the first thing is it has to be fully informed consent, which means that you have to explain to people what that risk is. The important thing about aspirin is that doctors have a much worse opinion of it than it deserves because if you work in a hospital, you'll often see people coming in who've had a bleed. [00:16:48] It's not always caused by the aspirin. The thing is, if you're coming with a bleed and you're on aspirin, everyone blames the aspirin. Right. About half of them would've happened anyway. In fact, the, the irritation of the stomach is much more of a problem in older people So in fact, the average age of the people in CaPP2 and CaPP3 was about 45, 46 when they started. [00:17:08] Drew was a little bit older, but, but people in that sort of middle age group are much, much less likely to get into trouble than people in their 70s and 80s. And it's people also who've had a history of ulcers that have a bigger problem. We also knew that if you had a stomach infection called H. Pylori, which is itself a risk factor for cancer, and about one in six people carry that bug, and we knew that if we fixed that with antibiotics, that would significantly reduce the risk of bleeding as well. [00:17:37] So it was a manageable risk. It was something we could share with people. They knew they were taking a bit of a chance. But actually a good way of putting it in terms of the risk, for people in middle age, the risk of a low dose of aspirin is about the same as the risk of having a colonoscopy, which is very small, but it isn't completely without risk. [00:17:56] Sharon: Yeah, and Drew, kind of like hearing this sort of incredible, like, backstory about how we've got to these trials and where we are today What was your experience like as a kind of participant of this trial? [00:18:08] Drew: I understood I was going to be on 100, 300, or 600, but wouldn't know for at least three years, or was it five years? I can't remember. [00:18:15] And then sometime later in the post we got these packs, and it was ... I remember at the time thinking it was like a rather dull advent calendar - ... in that you'd have the days of the week- ... with the little, with the little windows, and you'd, you'd pop the tablets out three times a day and take them. [00:18:31] So I did that. I think, you know, I, I don't think I ever missed a day or whatever. Initially, I thought I must be on a really low dose, because I didn't actually notice any side effects. You know, I remember saying to my wife, I said, "Oh, I think I must be on the lowest dose, because I don't see any side effects." [00:18:46] It was a surprise years later when I was told actually I'd been taking 600, so. [00:18:51] Sharon: Wow. [00:18:52] Drew: It was quite an easy experience really. [00:18:54] John: We had a lot of problems. We had to pack the aspirin in six-month packs, because it was very expensive to pack this stuff up. It cost... We got the aspirin free from the Bayer company, but it cost us more than a million pounds to actually put it in, in the packs to satisfy the regulations. [00:19:10] Uh, and a lot of people complained that the packs were a bit big and awkward, but that was just, you know, a constraint. But it was not that big a deal once people got into it. But we did get a lot of complaints about the size of the packets, which we couldn't do anything about that. [00:19:24] Drew: They came regularly through the post, and, you know, so every three months or whatever I got another supply, and I just carried on taking them. [00:19:30] Yeah, so. [00:19:31] Sharon: What was going through your mind when you were kind of waiting for this potential outcome, Drew? Because you, like you say, it was, you know, it was a long time taking part. What was... Especially as you were opening your, you know, your package a day, knowing exactly what you were going to get. [00:19:44] Drew: Well, I, I kind of knew it would be a long-term thing. [00:19:47] I think I was committed for five years initially. But I carried on taking the aspirin for another probably five years after that. So yeah, I was just sort of happy to take the aspirin and then sort of wait to see what the results would be. As I say, that I didn't really notice any side effects, so I wasn't really worried that it was having any detrimental effect on me. [00:20:09] So I was curious to see what the, what the results would be. [00:20:12] Sharon: Yeah. John, the trial has provided like the evidence that, you know, low-dose aspirin can prevent bowel cancer. But are there any challenges that still exist with translating this research into clinic and ultimately patient care? [00:20:26] John: Well, yes, and I'm going to hand back to Katie, who's actually leading the charge on, on getting it into practice as well. [00:20:32] But just to say that I, I'm actually now literally on my other computer finalising my bid to go back to Cancer Research UK because we want to go for three more years. Wow. We said that we would follow people for 10 years after they'd finished their ... or after they'd started, so, you know, for at least 10 years. [00:20:50] So the last person to join didn't finish until 2024, so we won't get to that person. It's Robin and one of my patients. We won't get to Robin's 10-year anniversary until 2029. Oh, yeah. By which time, obviously, Drew will be even further on. But that will give us at least 10 years of follow-up because we know that there is this delayed effect, and that was seen right back at the beginning when people looked, for example, the nurses study in America, where they followed 86,000 nurses and just asked them if they took aspirin. [00:21:18] And nothing happened for 10 years, but those who were taking aspirin for more than 10 years saw a benefit. So in the general population, it probably takes that long to kick in. And so we need to keep going for just a while longer. It's not as expensive now because we're not giving people aspirin anymore. [00:21:33] Sharon: Yeah. [00:21:34] John: But one of the reasons we g- we made Drew's dose blind was because we wanted to know what the side effects would be when you didn't know how much you were getting There's a danger if you're getting a higher dose, you're more likely to complain. And actually, it did work out that the people on the lowest dose had the fewest side effects, even slight side effects. [00:21:51] The only thing we can't escape from is if you're taking aspirin, you get bruising more easily because it blocks the platelets, which are the little tiny blood cells which plug up little holes in your blood vessels when they leak. The good news is we now know that platelets turn out to be right, a major factor in triggering cancer. [00:22:09] And so the aspirin, by blocking the platelets, is actually reducing the risk of cancer, but also reducing the risk of cancer spreading in the body. So this is new research, and we've got another big research project in collaboration with a team in Cambridge who are, uh, pursuing this. Also, the other exciting news is that my other partner, Ruth Langley, is running a big trial of people with cancer, and those who are given aspirin as part of their treatment have less likelihood of getting spreading cancer later on. [00:22:39] So the aspirin is clearly doing something good at many levels in the system. Surprisingly, and we think it might be partly, partly because we used to have a lot of salicylate in our diet, which is what aspirin's made from. And we think that maybe we're putting back something that the body actually was used to having. [00:22:57] Yeah. But modern diets don't contain any, any salicylate because of the way we prepare our food. So it may well be that a little bit of aspirin's a good thing for everybody, but obviously, that's a choice that each person will have to make. [00:23:09] Sharon: Yeah. I mean, it's a real powerhouse of a, of a drug essentially, which you're finding out more about its benefits as, uh, as research goes on. [00:23:18] So Katie, can you just give us a bit of a broad overview of Genomics England's new adults program, which is kind of looking at this sort of area of work and, and what, how can it benefit people? [00:23:29] Katie: Yeah. Thank you, Sharon. So, the adults programme at Genomics England is being funded by government, and the government wrote about it in the 10-year NHS Health Plan, the Life Science Sector Plan to run a large-scale genomics population study. [00:23:44] So looking at how we can obtain genetic information from people in the population and look at more proactive and preventative healthcare, and can we generate evidence on where, how, and why the NHS should start applying genomics into kind of more population health measures. So, there's sort of two sides to this. [00:24:05] So the first is thinking about pharmacogenomics, which is basically about how genetic factors influence how we respond to drugs. So lots of people have had experiences of having side effects from drugs, we've just been talking about that with aspirin, or for drugs not working so well for them. And we know that there are certain drugs that genetic factors can influence whether you should take the drug at all, or if you do, what dose you should take, whether it's going to work for you or not, whether you might be more likely to get side effects or adverse reactions. [00:24:34] So part of the programme's looking at that. And then the other half of the programme will be looking at sort of is, are the genetic factors relevant for sort of serious and high-risk conditions in the adult population? So we could take bowel cancer as an example of that, a common condition, breast cancer, you know, common cancers or cardiovascular disease. [00:24:58] We know there are certain genetic factors for some people that have significantly increased their chance of developing those serious adult onset conditions. Can we find those people in the population and then put measures in place to prevent that? So, you know, even just thinking about Drew's story, he didn't have a family history of cancer. [00:25:16] The first time that he knew he had Lynch syndrome, he'd already developed bowel cancer. And we know that many people that have Lynch syndrome or other high-risk cancer genes are unaware of their status in the population, and so, um, the idea of this program is to really look at, well, if we were to, to look for some of these very high-risk genes in the general population, could we then put measures in place to reduce the chance of them developing the serious condition as a consequence? [00:25:44] So instead of Drew presenting with his bowel cancer, we'd actually already picked it up, despite the fact he doesn't have a family history, and we'd offered him, let's say, aspirin if we'd known the information at the time, and we could maybe have prevented him from developing bowel cancer. [00:25:58] So it's really exploring looking at that a little bit more. [00:26:02] Where can we get genetic information in the population? Where might there be a really well-evidenced, like all the work John's done over 40 years, is really well-evidenced now. Yeah. Yeah. Where are there these opportunities for us to turn the dial on some of these common adult onset conditions? [00:26:20] Sharon: What other challenges do you think with getting this out there do you see? [00:26:25] Katie: Uh, I think there's, there's lots of challenges. I think it's a really com- ... complex programme of work. The first thing is that the risks might be different for people in a population than have a family history. So where I've worked for, for years, and John as well in, in clinical genetics, we've seen the highest risk people, the people with lots and lots of cancer in their family because they're the people that are presented to healthcare services. So we've worked out the risks based on that population. It will be really different when we move to the population setting. We'll find fewer people, and the risks might be lower because there might be other factors that are giving them a lower risk. But that's not to say the risk is zero. [00:27:05] It's probably still raised. So then what we need to do is we need to consider, okay, well, what can we do to intervene, taking into account this change of context from people that we found through clinical services to people that we see in the population. And aspirin is a great example of this. [00:27:22] So, you know, if we find that someone has a Lynch syndrome gene, then taking aspirin, unless there's a really good reason for them not to take aspirin, is almost certainly going to be low cost to the NHS and really significantly reduce the chance of them developing bowel cancer with a low risk profile. So where are those opportunities? [00:27:41] And that isn't clear cut, and that's why we need a large scale research programme that can try to help the NHS answer some of those questions, so it can decide how best to spend its money in, in the people that are most likely to benefit from it with the least amount of risk or harm to them. [00:27:58] Sharon: That makes sense. And, and so, you know, going to you, Drew, what are your kind of thoughts on some of the challenges that Katie's highlighted? And is there anything else that you think needs to be improved in better supporting people living with inherited risk of cancer in the future? [00:28:14] Drew: In the brief sort of 10, 15 years or whatever since I've been s- suffering, awareness has increased greatly. [00:28:21] I mean, for example, my GP now knows about Lynch syndrome, whereas I don't think she did when I was first diagnosed, and I think there is a little bit more awareness out there, but I still think it's a lot less than there would be for, say, for breast cancer. So for example, when a high-profile personality reveals they've got breast cancer, you often get information about inherited risks. [00:28:44] You don't seem to get that with colon cancer. You know, when it's announced that so-and-so has died or is whatever, you don't get that same, you know, it, it might be a genetic thing. I mean, when I was first told people that I had bowel cancer, the response I got usually was, "Oh, poor diet, was it?" [00:29:04] And I always felt a bit upset, that, you know, actually my diet was fairly healthy. And that was the assumption that people had. So I think anything that gets the message out there that there is a risk, an inherited risk, I'm not sure what the statistics are now, Katie, is it one in 400 people might be a Lynch syndrome carrier or something like that? [00:29:24] You know, it's relatively high for something that is, if you know in advance you're at risk, you can do something about it. But like me, you know, I waited until it was too late, because I didn't know, and then had to have the surgery, so anything that promotes the message that there is a risk. I know some people don't want to know about their genetic makeup. Obviously, that's a choice. But I think to give people, as many people as possible, the choice must be a good thing. [00:29:54] Sharon: Yeah, absolutely. And I think one thing I've noticed through this thread is the sort of theme of funding and what gets funding and the amount of time it takes to, to kind of get that funding. [00:30:05] Is there anything you wanted to add around the kind of funding model, around why some things get funded, you know, uh, more prominent, like Drew's point, obviously, talks about if someone high profile kind of comes forward and says XYZ, that gets the spotlight shone on it, and there might be research going that direction compared to s- to, to other cancers. [00:30:23] John: So maybe I could speak at that. So partly because of my experience, I've now been made chairman of the grant committee at Cancer Research UK for prevention and population research. And there is a real drive to push more resource into prevention for the obvious reasons. [00:30:39] Katie: Yeah. [00:30:39] John: And also, it's got to be remembered, it's very difficult for the drug companies to fund this because it takes such a long time that the drug's- Mm [00:30:46] out of its patent before they actually get to use it. So, it's very difficult from a business point of view to fund research into prevention. But they are keen to help us, uh, but we really need sort of central government and the charities to focus on prevention if it's going to make a difference. [00:31:02] And just on Drew's point on diet, I mean, diet is still important even if you have Lynch syndrome. In our CaPP2 trial, the people who were overweight were more than double the risk of cancer. So it's not like an either/or. If you've got a higher genetic risk and you have a bad diet, then that's, you know, is going to contribute. [00:31:21] But the other exciting thing is, of course, we now have medical ways of treating obesity in, in people. So, one of the interesting areas is whether we should be, in the same way as we are for other high-risk populations with overweight, we should be giving overweight people with Lynch syndrome, help to lose weight because that will also reduce their risk. [00:31:41] It's also worth just dropping in at the last moment here is that this is also a good news story in terms of treatment and further prevention. We now have a new class of drugs called immune checkpoint inhibitors, which specifically target the types of cancer that Drew had and are much more effective in curing them And also, we've just been given funding to do a project called LynchVax, which I'll be helping with, but it's led by David Church in Oxford. [00:32:05] And this is developing a vaccine against cancers in people with Lynch syndrome. The great news is it'll probably work alongside aspirin because we know the aspirin is enhancing the immune response. So the two together may make this a curable condition. [00:32:18] Sharon: That's actually incredible. I mean, that, it gives so much hope for people. [00:32:23] And I just wanted to find out if you had any more kind of reflections as we close, because we're going to come to the end of our podcast today. If there's anything more that you wanted to share, anything that has been missed, or anything that you want our listeners to know, and I think I'm gonna come to you, Drew, first, because you're the person who's had to sort of live through this and, and go through this journey along the way. [00:32:41] Drew: I think just basically, if you're not sure, get tested. Obviously, there are financial constraints. I'm sure that running a DNA test is quite an expensive business. But I think if you've got any history of bowel cancer in the family, you've got any concerns about your health, speak to a GP and see if you can get tested as quickly as possible. [00:33:00] And then, to get a better message out there that there are risks of inherited colon and other similar cancers, so. [00:33:11] Sharon: Yeah, so it's getting that, messaging out, um, for people to understand more and make those informed choices. And Katie? [00:33:18] Katie: I mean, I would say that the power of, of our, you know, NHS and our academia and, and our healthcare system has been collaboration. [00:33:26] Sharon: Yeah. [00:33:27] Katie: There's so many moving parts. There's commissioners, there's funding, there's the evidence, there's research, there's healthcare implementation. The UK's a really amazing place to work in genomic medicine, and I think that's partly because of the amazing collaborations that we have, and the way that we can translate research into healthcare as John's team have done with this amazing study. [00:33:48] So let's all keep working together, please. [00:33:52] Sharon: Absolutely. And John, it feels like this is your lifetime's work. [00:33:58] John: Well, I've become aspirin man, it wasn't intended. But Katie's done fantastic work in her role as chair of the Cancer Genetics Group in the UK, so we've now implemented a, [00:34:06] we're the first in the world to really make this an absolute directive to the GPs and all, to all doctors to say, "People with Lynch syndrome need to be offered aspirin." And so that's a great step forward. But we also need to get it into the British National Formulary, and I'm working with their team so that the GPs are empowered to do this. [00:34:24] It's actually part of their care package. But I would just say we've still got a long way to go. We've now got a national list of all the people with Lynch syndrome, like Drew, to make sure we offer them all a colonoscopy, but there are only 14,000 people after several years of really pushing. [00:34:40] Sharon: Right. [00:34:40] John: We think in the national population in all ages, it's about 1 in 300. That's a lot of people. That means there's about 150,000 people like Drew in the country, and we've only found 10% of them. So we can't just rely on family history for all the reasons Drew explained. You know, I mean, Drew's dad probably died of Lynch syndrome, but we don't know because we've lost that record. [00:35:02] So now we're checking every bowel cancer to see if it might be caused by Lynch, and that programme is now kicking in, and we're picking up a lot more gene carriers as a result of that. But there's still a long way to go to get co- get people aware of Lynch syndrome, to think of it when someone presents with a cancer, not just of the bowel, but in the womb, in the kidney, in other parts of the body. [00:35:23] It's not just the bowel, but that's the most important group. [00:35:26] Sharon: Yeah. [00:35:26] John: So there's still a long way to go. [00:35:28] Sharon: Where you've come to now is still an incredible achievement, even though we've still got a long way to go, and I don't think we should ever lose sight of that. So we're going to wrap it up there. Thank you to our guests, Katie Snape, Professor Sir John Burn, and Drew Hyde, for joining me today as we discuss cancer prevention. [00:35:48] If you'd like to hear more like this, please subscribe to Behind the Genes on your favourite podcast app, and thank you for listening. I've been your host, Sharon Jones, and Behind the Genes is produced by Deanna Barac, Florence Cornish, Sophie McLachlan, and Dave Howard at Bespoken Media.  

Have you ever stayed in the bath or swimming pool for ages and noticed that your fingers and toes went all wrinkly? Well, 11-year-old Maya from London wanted to know why that happens.She joins host Eloise to get the answer from biologist Tom Smulders from Newcastle University on the first episode of our second season! There's an experiment in this episode which you can try out too while you listen. If you want to join in, prepare a bowl of warm water.A podcast from The Conversation, the independent not-for-profit news organisation that brings you news and analysis straight from academic experts. Full credits available here.This season is supported by the University of Southampton in the UK, a world-leading research-intensive university with a global network of international students and campuses in Malaysia and Delhi. Are you a curious kid with a question? Pop it in an email, or record it and send us the audio to curiouskids@theconversation.com.

In this episode, I speak with Rob Wood, Portfolio Investor and Founder of the Rob Wood Enterprising Futures Academy, about entrepreneurship, scale, reinvention and widening access to enterprise. Rob founded STEM Healthcare in 2007, scaling it internationally before its acquisition by UDG Healthcare. Today, he is an active portfolio investor, working with technology-enabled pharma services and AI-driven healthcare businesses, including AdvanceAI. Through the Rob Wood Enterprising Futures Academy, created in partnership with Newcastle University in the UK, he is also helping young people build the confidence, tools and support to succeed in life and business. Connect with Shirley at ShirleyKavanagh.com and on LinkedIn. To learn more about Rob's work, visit the Rob Wood Enterprising Futures Academy or connect with him on LinkedIn

In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, an academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MD, a consultant rheumatologist at Freeman Hospital, Newcastle, are joined by guest Lucy Carter, MBBS, PhD, a consultant rheumatologist at Newcastle upon Tyne NHS Foundation Trust and honorary clinical senior lecturer at Newcastle University, to examine nearly 2 decades of B cell–targeted therapy in rheumatic disease — a story that has proven considerably more complicated than its early promise suggested.Carter, Arnold, and Buss trace the mixed legacy of rituximab in lupus and Sjögren disease and examining how incomplete B cell depletion, BAFF-driven rebound, and trial design limitations may have contributed to disappointing early results. The discussion then turns to newer approaches such as obinutuzumab, whose positive REGENCY and ALLEGORY trial data in lupus nephritis and systemic lupus erythematosus suggest that deeper, more durable B cell depletion may improve outcomes, while emerging CAR-T data raise broader questions about the future role of intensive immune reprogramming in autoimmune disease.

What was life like for young people in twentieth century Britain? In We Have Come to Be Destroyed: Growing Up in Cold War Britain (Yale University Press, 2026), Dr Laura Tisdall, a Senior Lecturer in Modern British History at Newcastle University tells the story of this era through the eyes of children and young people, offering a radical reinterpretation of Britain's Cold War age. The book offers a wide range of perspectives, from young people's hopes and anxieties for the future, through popular culture during the Cold War, to changes in schools and the education system. The analysis also draws on detailed engagements with feminist and gay rights campaigns, and highlights the experiences of young people of colour, blending microhistories of individual experience with a broader narrative that transforms our existing knowledge of the Cold War. The book will be essential reading across the arts and humanities, as well as for social science scholars and anyone interested in knowing more about recent British history. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

What was life like for young people in twentieth century Britain? In We Have Come to Be Destroyed: Growing Up in Cold War Britain (Yale University Press, 2026), Dr Laura Tisdall, a Senior Lecturer in Modern British History at Newcastle University tells the story of this era through the eyes of children and young people, offering a radical reinterpretation of Britain's Cold War age. The book offers a wide range of perspectives, from young people's hopes and anxieties for the future, through popular culture during the Cold War, to changes in schools and the education system. The analysis also draws on detailed engagements with feminist and gay rights campaigns, and highlights the experiences of young people of colour, blending microhistories of individual experience with a broader narrative that transforms our existing knowledge of the Cold War. The book will be essential reading across the arts and humanities, as well as for social science scholars and anyone interested in knowing more about recent British history. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/gender-studies

What was life like for young people in twentieth century Britain? In We Have Come to Be Destroyed: Growing Up in Cold War Britain (Yale University Press, 2026), Dr Laura Tisdall, a Senior Lecturer in Modern British History at Newcastle University tells the story of this era through the eyes of children and young people, offering a radical reinterpretation of Britain's Cold War age. The book offers a wide range of perspectives, from young people's hopes and anxieties for the future, through popular culture during the Cold War, to changes in schools and the education system. The analysis also draws on detailed engagements with feminist and gay rights campaigns, and highlights the experiences of young people of colour, blending microhistories of individual experience with a broader narrative that transforms our existing knowledge of the Cold War. The book will be essential reading across the arts and humanities, as well as for social science scholars and anyone interested in knowing more about recent British history. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/critical-theory

What was life like for young people in twentieth century Britain? In We Have Come to Be Destroyed: Growing Up in Cold War Britain (Yale University Press, 2026), Dr Laura Tisdall, a Senior Lecturer in Modern British History at Newcastle University tells the story of this era through the eyes of children and young people, offering a radical reinterpretation of Britain's Cold War age. The book offers a wide range of perspectives, from young people's hopes and anxieties for the future, through popular culture during the Cold War, to changes in schools and the education system. The analysis also draws on detailed engagements with feminist and gay rights campaigns, and highlights the experiences of young people of colour, blending microhistories of individual experience with a broader narrative that transforms our existing knowledge of the Cold War. The book will be essential reading across the arts and humanities, as well as for social science scholars and anyone interested in knowing more about recent British history. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/lgbtq-studies

What was life like for young people in twentieth century Britain? In We Have Come to Be Destroyed: Growing Up in Cold War Britain (Yale University Press, 2026), Dr Laura Tisdall, a Senior Lecturer in Modern British History at Newcastle University tells the story of this era through the eyes of children and young people, offering a radical reinterpretation of Britain's Cold War age. The book offers a wide range of perspectives, from young people's hopes and anxieties for the future, through popular culture during the Cold War, to changes in schools and the education system. The analysis also draws on detailed engagements with feminist and gay rights campaigns, and highlights the experiences of young people of colour, blending microhistories of individual experience with a broader narrative that transforms our existing knowledge of the Cold War. The book will be essential reading across the arts and humanities, as well as for social science scholars and anyone interested in knowing more about recent British history. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/british-studies

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning spoke with Dr. Enoch Akowuah, an academic consultant cardiothoracic surgeon at Newcastle University and South Tees NHS Foundation Trust, UK, and Dr. Matthias Raschpichler, a cardiac surgeon at Leipzig Heart Center, Germany, about the REPEAT trial. Chapters 00:00 Intro 02:21 JANS 1, NOBLE Trial 07:14 JANS 2, Ischemic Mitral Regurg MVR 08:58 JANS 3, Pregnancy Outcomes AVR 11:19 JANS 4, MCS LVAD Candidates 13:06 Video 1, Thoracoplasty 14:58 Video 2, Nuss Procedure After Ravitch 16:42 Video 3, Traumatic Right Main Bronchus 19:04 REPEAT Trial, Bioprostheses 32:22 Upcoming Events 32:46 Closing They discussed the trial's objectives, including what it is, why it is needed, and its overall goals. The setup of the trial was also examined, covering aspects such as funding, composite outcome, and follow-up procedures. Additionally, they addressed the target number of patients required for recruitment and the efforts involved in recruiting patients and centers to participate in the trial. They emphasized the overall significance of the trial, outlining what is necessary for its success and highlighting the importance of collaboration among heart teams. Joel also highlights recent JANS articles on percutaneous coronary intervention vs coronary artery bypass grafting for unprotected left main stenosis, a two-decade experience on the outcomes of mitral valve repair in ischemic mitral regurgitation, maternal, valvular and fetal outcomes of pregnancy following aortic valve replacement, and temporary mechanical circulatory support in left ventricular assist device candidates with right ventricular dysfunction. In addition, Joel explores if forgotten techniques of thoracoplasty with latissimus dorsi myoplasty are relevant today, the Nuss procedure after previous Ravitch operation, and uniportal VATS repair of traumatic right main bronchus transection following blunt chest injury. Before closing, Joel highlights upcoming events in CT surgery.   JANS Items Mentioned Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting for Unprotected Left Main Stenosis: 10-Year Final Results From the Randomised, Open-Label, Non-Inferiority NOBLE Trial Outcomes of Mitral Valve Repair in Ischemic Mitral Regurgitation: A Two-Decade Experience Maternal, Valvular and Foetal Outcomes of Pregnancy Following Aortic Valve Replacement  Temporary Mechanical Circulatory Support in Left Ventricular Assist Device Candidates With Right Ventricular Dysfunction: Acuity Without Long-Term Futility CTSNet Content Mentioned Are the Forgotten Techniques of Thoracoplasty With Latissimus Dorsi Myoplasty Relevant Today?  Nuss Procedure After Previous Ravitch Operation  Uniportal VATS Repair of Traumatic Right Main Bronchus Transection Following Blunt Chest Injury  Other Items Mentioned The REPEAT Trial Career Center CTSNet Events Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

In this episode, Ray Cochrane breaks down a reversible conductive glue from Newcastle University that could replace solder and finally make electronics recycling work. Additional stories cover China widening its clean energy lead, DeepMind’s AlphaEvolve scoring wins from genomics to Google’s database, Anthropic’s $200 million partnership with the Gates Foundation, Intel teaming up with McLaren Racing, and end-to-end encrypted RCS rolling out in beta. – Want to start a podcast? Its easy to get started! Sign-up at Blubrry – Thinking of buying a Starlink? Use my link to support the show. Subscribe to the Newsletter. Email Ray if you want to get in touch! Like and Follow Geek News Central’s Facebook Page. Support my Show Sponsor: Best Godaddy Promo Codes Get 1Password Full Summary Cochrane opens the show with a deep dive into Newcastle University’s reversible conductive glue, a water-based adhesive that could finally make electronics recycling economically viable. He frames the e-waste problem first: 62 billion kilos a year, with less than a quarter ever recycled. Then he walks through the silver nanoparticle chemistry, the lead-free angle on traditional solder, and the geopolitical stakes of critical mineral recovery. From there the episode pivots through energy, AI, hardware, open source, data research, space, science, and consumer privacy. A Reversible Conductive Glue That Could Replace Solder A team at Newcastle University has developed a water-based glue that conducts electricity well enough to replace solder. Unlike solder, however, the glue releases cleanly with a quick rinse of acetone or an alkaline bath. The breakthrough relies on silver nanoparticles suspended in a water-based binder. Consequently, components can be recovered intact, opening a viable path to electronics recycling at scale. Co-investigator Volker Pickert framed the second prize directly: solder has the best conductivity, but the best formulations contain lead. China Widens Its Clean Energy Lead A new Atlas Public Policy report shows Chinese firms accounted for 55 percent of $1.1 trillion in global clean energy manufacturing investment between 2019 and 2025. Battery manufacturing alone pulled in nearly half of that money. Meanwhile, U.S. companies have actively retreated from those same industries. With the Strait of Hormuz currently closed, supply chain ownership in solar, wind, and batteries matters more than ever. A separate Ember analysis showed Chinese solar panel exports doubled in March alone. DeepMind’s AlphaEvolve Scores Real Wins DeepMind published an update on AlphaEvolve, its Gemini-powered AI coding agent. The system cut genomic variant detection errors by 30 percent. Additionally, it lifted AC Optimal Power Flow feasibility from 14 to over 88 percent on the electrical grid. AlphaEvolve also found a better cache replacement policy in two days that would have taken human engineers months. Furthermore, it reduced write amplification in Google’s Spanner database by 20 percent. The pattern shows applied AI sticking, not as a chatbot but as a quiet optimizer. Anthropic and Gates Foundation Commit $200 Million Anthropic announced a four-year, $200 million partnership with the Gates Foundation across three pillars. The biggest pillar targets global health and life sciences in low and middle-income countries. Notably, the research scope includes polio, HPV, and preeclampsia. A second pillar covers AI in education across the U.S., sub-Saharan Africa, and India, in partnership with the Global AI for Learning Alliance. Finally, an economic mobility pillar focuses on agricultural productivity and crop benchmarks. Google’s AI Educator Series Launches Free Google rolled out the first 20-plus sessions of its AI Educator Series this week. The free AI literacy training targets the roughly 6 million K-12 and higher education teachers across the U.S. Modules are designed as short, snackable trainings teachers can finish in a prep period or a lunch break. Additionally, stackable workshops let educators build credentials over time. Importantly, the program requires no institutional subscription. Amazon Bedrock Prompt Optimization Goes GA Amazon Bedrock dropped its Advanced Prompt Optimization tool, now generally available across most major regions. The feature rewrites prompts to perform better on specific models and automates prompt migration when switching between models. Furthermore, a built-in evaluation feedback loop lets users benchmark against up to five models side by side. The default judge model is Claude Sonnet 4.6. Consequently, teams can stop hand-tuning string templates and focus on product work. Sponsor: GoDaddy Economy hosting $6.99/month, WordPress hosting $12.99/month, domains $11.99. Website builder trial available. Use codes at geeknewscentral.com/godaddy to support the show. Arm AGI CPU and Red Hat Go Production-Ready on Agentic AI Arm and Red Hat expanded their collaboration around Arm’s AGI CPU, which is Arm’s branding for its agentic AI chip family. The deal brings Red Hat Enterprise Linux and OpenShift to the chip as a production-ready stack. Hardware specifications include 136 Neoverse V3 cores, 96 PCIe Gen6 lanes, and 12 channels of DDR5-8800 memory in a 300-watt thermal envelope. Availability lands in Q4 through Supermicro, Lenovo, and ASRock Rack. Intel Becomes McLaren Racing’s Official Compute Partner Intel announced a multi-year deal as the official compute partner for McLaren Racing. The agreement covers the McLaren Mastercard Formula 1 team, Arrow McLaren IndyCar, and McLaren F1 Sim Racing. Trackside edge compute will power real-time race decisions, while Xeon and Core Ultra silicon drive Computational Fluid Dynamics and digital twin work. Consequently, design iterations that once took weeks now collapse to days. The deal puts Intel silicon in front of every CTO watching a Grand Prix. Rust Lands 13 Google Summer of Code Projects The Rust Project landed 13 accepted projects in Google Summer of Code 2026. Out of 96 proposals, a 50 percent jump from last year, the project selected 13. Notably, three returning contributors from prior years are back. Mentors flagged a noticeable share of AI-generated submissions as a growing challenge. Furthermore, the real bottleneck remains mentor capacity rather than funding. GitHub Innovation Graph Maps Digital Complexity Researchers used GitHub Innovation Graph data to predict GDP, inequality, and emissions through the Economic Complexity Index, or ECI. Countries are compared to kitchens; the more variety and sophistication in software output, the higher the score. Germany ranks first, followed by Australia and Canada. The U.S. lands at sixth. However, the dataset only captures public GitHub activity, leaving most proprietary software invisible. NASA and Eta Space Prepare Cryogenic Fuel Demo NASA is teaming with Eta Space on an in-orbit demonstration called LOXSAT, short for Liquid Oxygen Flight Demonstration. The nine-month mission tests cryogenic fluid management techniques required for in-space propellant depots. Launch is no earlier than July 17 aboard a Rocket Lab Electron from the Mahia Peninsula in New Zealand. Successful refueling in orbit could reshape what is possible for deep-space missions to the Moon and Mars. Stealth Magma Surge Under São Jorge Surprises Researchers Researchers in the UK and Spain published in Nature Communications on a 2022 magma surge under São Jorge Island in the Azores. The surge climbed from more than 20 kilometers underground to 1.6 kilometers below the surface. Surprisingly, most of the thousands of earthquakes happened after the magma stalled, not during the climb. Consequently, scientists are calling it a stealth surge and a failed eruption. A primed magma chamber now sits closer to the surface than before. End-to-End Encrypted RCS Begins Rolling Out Apple and Google led a cross-industry effort to roll out end-to-end encryption for RCS messaging. As of May 11, the feature is rolling out in beta on both platforms. Importantly, encryption is on by default and auto-applies to new and existing conversations. A lock icon in the chat indicates active end-to-end encryption. This quietly raises baseline privacy for billions of cross-platform messages. Cochrane signs off with the usual ecosystem mentions: GNC Insider at geeknewscentral.com/insider, the show newsletter, and modern podcast app recommendations at podcastapps.com. The post A Reversible Glue that could Replace Solder #1865 appeared first on Geek News Central.

At just 27, Ali Hashemizadeh is doing things most dentists twice his age haven't managed — two private associate roles, a growing reputation as an endodontist, and the kind of self-awareness that usually takes a decade to develop. In this episode, Payman sits down with the Newcastle-based, Aberdeen-raised, Iranian dentist to trace the path from a rocky first year on the NHS to finding his feet in private practice. Ali talks candidly about the complaint that rocked him early in his career, the perspective shift it forced, and why he's genuinely glad it happened. It's a conversation about curiosity, resilience, and the quiet power of just cracking on.In This Episode00:00:50 – Introduction: Ali Hashemizadeh00:03:45 – Lifelong learning00:07:25 – The future of dental events00:14:30 – Optimism as a work philosophy00:15:35 – NHS complaint, first job00:19:40 – Resilience and perspective00:21:10 – Going private early00:22:25 – Becoming the endo guy00:25:55 – Generalist or specialist?00:26:50 – The disease of the twenties00:28:30 – Iranian roots in Aberdeen00:38:15 – Foundation year in London00:40:55 – Outdoor pursuits and Ironman training00:46:10 – CBCT and safe-ended files00:50:05 – Endo, implants and aesthetics under one roof00:52:00 – Treatment coordinators and ethical selling00:57:15 – The value of mentorship00:59:00 – Networking and landing the jobs01:02:55 – The two practices compared01:07:35 – Lucas Lassman and the most inspiring lecture01:10:40 – Dental resources: YouTube and Instagram01:15:10 – Being Mortal and Man's Search for Meaning01:16:30 – Modern Wisdom and guilty pleasures01:22:35 – Ten-year plan01:27:40 – Fantasy dinner partyAbout Ali HashemizadehAli Hashemizadeh is a 27-year-old private associate dentist working across two practices in the northeast of England — Middleton Saint George Dental in Darlington and Ken Harris's clinic in Sunderland — where he has developed a particular focus on endodontics. Born and raised in Aberdeen to Iranian parents, he qualified from Newcastle University and completed his foundation year in London before heading back north.

How teachers and students are using AI at school and beyond. About John Dolman John Dolman is a Media Studies teacher at Ponteland Community High School. He holds an MEd in Educational Leadership and Practitioner Enquiry and a Postgraduate Certificate in Education from Newcastle University. He has worked in schools in the UK, Malaysia and the United Arab Emirates, teaching English and Media and holding leadership roles including Head of Languages and Cultures and Raising Achievement Deputy. His responsibilities have included curriculum development, teacher training and mentoring, data analysis, and performance management. He is interested in using AI and generative AI in practical ways to support teaching and learning. Outside of work, he enjoys the outdoors, practises martial arts, and cares about the environment and his local community. LinkedIn: https://www.linkedin.com/in/john-dolman-3836b8251/  Resources https://theaienglishteacher.wordpress.com/  https://activelyintelligent.org/about John Mikton on Social Media LinkedIn: https://www.linkedin.com/in/jmikton/ Twitter: https://twitter.com/jmikton Web: beyonddigital.org Dan Taylor on social media: LinkedIn: https://www.linkedin.com/in/appsevents  Twitter: https://twitter.com/appdkt  Web: www.appsevents.com Listen on: iTunes / Podbean / Stitcher / Spotify / YouTube Do a full security audit of your Workspace for free at https://workspaceaudit.com Would you like to have a free 1 month trial of the new Google Workspace Plus (formerly G Suite Enterprise for Education)? Just fill out this form and we'll get you set up bit.ly/GSEFE-Trial

Join Dr. Siobhan McCormack as she welcomes one of the top early-life microbiome scientists in the field, Professor Chris Stewart. Discover the origins of your gut microbiome, the biological superpowers of breast milk, and how lab-grown "organoids" are uncovering surprising ways to protect preterm babies.What We Cover:The Genesis of You: How birth mode and early feeding shape our microbial foundations.Inside the Stewart Lab: Using lab-grown human "organoids" to study host-microbe interactions in real-time.The Magic of HMOs: Why mothers produce complex sugars (Human Milk Oligosaccharides) that feed gut microbes instead of the baby.The "Good" Clostridium: Groundbreaking research on a specific Clostridium perfringens strain that thrives on HMOs to protect preterm infants from gut diseases.Probiotics & Preemies: Navigating FDA regulations and the future of personalized medicine in neonatal care.About Professor Stewart leads human microbiome research at Newcastle University. His lab combines computational biology with innovative wet-lab human organoid models to study global health issues, focusing primarily on the early-life gut microbiome and protecting vulnerable infants.Connect with the Stewart Lab:Newcastle University ProfileGoogle ScholarTwitterNewcastle Neonatal Nutrition and NEC Research (N4)Scientific References & Further Reading:Stewart CJ, et al. (2018). Temporal development of the gut microbiome in early childhood from the TEDDY study. Nature, 562(7728):583–8.Chapman JA, et al. (2026). Clostridia from preterm infants metabolize human milk oligosaccharides to suppress pathobionts and modulate intestinal function in organoids. Nat Microbiol, 1–20.Masi AC, et al. (2021). Human milk oligosaccharide DSLNT and gut microbiome in preterm infants predicts necrotising enterocolitis. Gut, 70(12):2273–82.Beck LC, et al. (2022). Strain-specific impacts of probiotics are a significant driver of gut microbiome development in very preterm infants. Nat Microbiol, 7(10):1525–35.UNICEF UK: Breastfeeding in the UKThis podcast is brought to you in collaboration with the British Society of Lifestyle Medicine.Disclaimer:The content in this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your doctor or qualified healthcare provider. Never disregard professional medical advice or delay in seeking it because of something you have heard on this podcast.

It's time for another BIG and BRILLIANT adventure into the world of science on this week’s Science Quest! In Science in the News, humans have travelled further into space than ever before as Artemis II orbits the Moon, scientists achieve a world first by mapping the DNA of a monkey, and Richard Wall from the University of Bristol joins Dan to explain the spread of a dangerous flesh-eating fly and why experts are keeping a close eye on it. It’s time for your questions too. Ryan wants to know why Earth spins on a wonky axis, and Brian Diffey from Newcastle University explains how your body makes vitamin D from sunlight. Dangerous Dan introduces the secretary bird, a fierce and fascinating hunter with a very unusual way of catching its prey. Then it’s time for Brain Box, where Dan’s high-tech question chamber puts top scientists to the test. This week, analytical chemist Kirsty Penkham takes on the challenge. Plus, in Kitchen Chemistry, K-Mistry explores the science of solids, liquids and gases, turning your kitchen into a chemistry lab. From deep space missions to DNA discoveries and dangerous insects, this episode is packed with brilliant science. What we learn about: • NASA’s Artemis II mission and its journey around the Moon• A world-first breakthrough in mapping monkey DNA• The threat of a flesh-eating fly• Why Earth spins on a tilted axis• How the body makes vitamin D from sunlight• The hunting skills of the secretary bird• The science of solids, liquids and gases All that and more on this week’s Science Quest!Join Fun Kids Podcasts+: https://funkidslive.com/plusSee omnystudio.com/listener for privacy information.

John Wilson onRobert Fox the producer who had a career that spanned theatre, film and television. We have tributes from Colin Firth, Rupert Everett and Robert's brother, the actor Edward Fox.Mary Rand MBE, the first British woman to win an Olympic athletics gold medal at the 1964 Tokyo Olympic Games.Sir Tony Hoare, one of the world's leading computer software designers who developed algorithms and languages which have become industry standards. Biruté Galdikas, the primatologist and conservationist whose years of studying orangutans in their natural habitat helped understand and protect the primates.Interviewee: Edward Fox Interviewee: Rupert Everett Interviewee: Colin Firth Interviewee: Wendy Sly Interviewee: Professor Bill Roscoe Interviewee: Professor Erin VogelProducer: Gareth Nelson-Davies Assistant Producer: Ribika Moktan Researcher: Jesse Edwards Editor: Glyn TansleyArchive used: Another Country movie promo, Another Country Trailer, 1984, director Marek Kanievska, writer Julian Mitchell, Goldcrest Films International,, YouTube Uploaded by Sundance Now, 04/10/2017; Another Country, Queen's Theatre, directed by Stuart Burge, written by Julian Mitchell, 1982, broadcast on Newsnight, BBC Two, 02/03/1982; Mary Rand at the 1964 Olympics, BBC Sound Archive, commentary by David Coleman, 1964 Tokyo Olympics, 14/01/1964; An Interview with Tony Hoare, ACM 1980 A.M. Turing Award Recipient, Interviewer: Cliff Jones, Newcastle University, 24/11/2015, uploaded to Association for Computing Machinery (ACM) YouTube channel on 25/10/2016; Biruté Galdikas interview, Good Morning, BBC One, 15/02/1995; Biruté Galdikas, Great Apes Documentary, BBC Two, 29/02/1976; Biruté Galdikas interview, Woman's Hour, BBC Radio 4, 16/02/1995;

KTRA 2025 Album (Ltd Ed USB Cassette) >>GRAB IT HEREGRAB IT HERE

New research suggests there's a simple way to get students match fit; let them wear sports gear all day rather than traditional uniforms. A study in collaboraton with Australia's Newcastle University found out of thousands of responses, more than three quarters supported the daily wearing of activity enabling sports uniforms. Newcastle University's Belinda Peden spoke to Lisa Owen.

With the war in Iran leading to the closure of the Strait of Hormuz, preventing or restricting oil and gas being exported from many of the Gulf states, the UK's energy policy has come to the fore once more. Proponents of renewables claim that a rapid shift to homegrown wind and solar power will spare us from the volatility of international supplies of fossil fuels. Critics argue the UK will need oil and gas for decades to come, but we can produce more, either in the North Sea or by fracking on land. This debate from the Battle of Ideas festival 2025 is, therefore, highly topical. Where should future energy policy go? ORIGINAL FESTIVAL INTRODUCTION In June 2019, the Conservative government amended the Climate Change Act to insert a target of ‘net zero' emissions by 2050. At the 2024 General Election, all the major political parties, with the exception of Reform, promised to back the goal, with any differences being about when to implement various policies, such as gas-boiler and petrol-car bans. Reform is well ahead in the opinion polls, and calling for the end of Net Zero and the resumption of fracking. Conservative leader Kemi Badenoch has said: ‘We've got to stop pretending to the next generation… Net Zero by 2050 is impossible.' Is Net Zero gradually being ditched? For proponents of the policy, climate change remains a clear and present danger. The energy and climate change secretary, Ed Miliband declared in May that Keir Starmer and Rachel Reeves are still backing Net Zero: ‘It's absolutely central to their economic growth and energy security, as well as climate agenda … So as far as I'm concerned, they are 100% committed to this agenda.' Labour has stopped new licences for gas and oil production in the North Sea and is committed to expanding renewable energy, with Miliband claiming: ‘People recognise that cheap, clean renewables beat expensive, insecure fossil fuels.' But fuel bills haven't fallen as the gas-price crisis of 2022 has faded. UK energy prices remain high by international standards, despite (or because of) the expansion of renewables, something highlighted by the need to rescue Scunthorpe steelworks. In June, it was reported that the government was planning to subsidise energy costs for energy-intensive industries. Sky News reported that in 2023, British businesses paid £258 per megawatt-hour for electricity compared to £178 in France and £177 in Germany, according to International Energy Agency data. Will the Net Zero consensus break down further – and should it? At a time when China's greenhouse gas emissions dwarf those of the UK and are still rising, does it make economic or environmental sense to decarbonise? Or does the threat of climate change demand that the UK takes a lead and we accept lower living standards to save the planet? SPEAKERS Jonny Ball contributing editor, UnHerd Dr Caspar Hewett lecturer, School of Engineering, Newcastle University; co-director, NERC FLOOD-CDT; director, The Great Debate Ruari McCallion freelance writer Ali Miraj broadcaster; founder, the Contrarian Prize; infrastructure financier; DJ Kathryn Porter consultant, Watt-Logic CHAIR Austin Williams director, Future Cities Project; honorary research fellow, XJTLU, Suzhou, China; author, China's Urban Revolution

Allen covers a week of offshore wind milestones including the Maersk Viridis sailing toward New York, Revolution Wind’s first power delivery, Vineyard Wind’s final blade, RWE’s Thor project in Denmark, and Kinewell Energy’s fundraise in England. Sign up now for Uptime Tech News, our weekly newsletter on all things wind technology. This episode is sponsored by Weather Guard Lightning Tech. Learn more about Weather Guard’s StrikeTape Wind Turbine LPS retrofit. Follow the show on YouTube, Linkedin and visit Weather Guard on the web. And subscribe to Rosemary’s “Engineering with Rosie” YouTube channel here. Have a question we can answer on the show? Email us! Good morning, everyone. There is a ship sailing toward America right now. And when it arrives, it will be the most powerful wind turbine installation vessel ever to work in United States waters. Her name is Maersk Viridis. Built by Seatrium in Singapore. Forty thousand tonnes of steel. A main crane reaching one hundred and eighty meters into the sky. Designed to lift the next generation of fifteen-megawatt turbines. At her naming ceremony, godmother Charlotte Norkjer Larsen smashed a bottle of champagne against the main crane pedestal. Viridis — the Latin word for green. The Viridis is headed for Equinor’s Empire Wind project off the coast of New York. When complete, five hundred thousand homes will have power. Now, there is something worth noting. This vessel was built as a Jones Act-compliant solution. That means it can work legally in United States offshore waters. It was built with zero lost time injuries. And while one great ship sails west, the wind industry is moving forward on every front. In New England, the Revolution Wind project delivered its first power to the grid. Seven hundred and four megawatts. Power enough for up to three hundred and fifty thousand homes. Built by local union workers logging more than two million hours. That same week, workers installed the last turbine blade on Vineyard Wind. A project that endured a fractured blade in July of twenty twenty-four, a legal battle to survive a federal stop-work order, and came out the other side — still standing. On the other side of the world, Denmark is doing what Denmark does. The first turbine is now installed at the Thor offshore wind project. In the North Sea, off the west coast of Jutland. When finished, Thor will be Denmark’s largest offshore wind farm. Seventy-two turbines. Each capable of fifteen megawatts. Each turbine rising one hundred and forty-eight meters above the sea. Total project capacity — one-point-one gigawatts. The installation vessel is the Brave Tern, operated by Fred. Olsen Windcarrier. She carries three turbines per trip. Some blades on Thor are recyclable. That is not a headline you could have written ten years ago. And the developer building Thor? That would be RWE. RWE is everywhere right now. Now, for a small story with a large idea behind it. In Wallsend, England, a twelve-person company called Kinewell just raised seven hundred and fifty thousand pounds. Founded by an engineer named Andrew Jenkins while he was earning his PhD at Newcastle University. Kinewell builds software — software that optimises the design of offshore wind farms. Cable layouts, turbine placement, transmission systems. All three, working together. Their clients include Equinor, SSE Renewables, and Eurus Energy. The new funding unlocks a further six-figure grant, bringing total new capital to more than one million pounds. Ten new jobs in the next six months. Their software has saved clients hundreds of millions of pounds. That is what the right tool can do. So let us step back and look at the week. A ship christened and sailing to New York. A New England grid receiving its first offshore wind power. Vineyard Wind — finished at last. Denmark’s largest wind farm, growing turbine by turbine. And a twelve-person software firm in northeast England, helping shape the invisible architecture of the energy transition. That is the Wind Energy News for the 16th of March, 2026. Join us for the Uptime Wind Energy podcast tomorrow.

Johnny Mac shares five good news stories: In Texas, Sean enlisted an entire preschool class to surprise his fiancée Zoey with a bridal shower; the couple had attended the school at age four and reconnected at a 2021 summer camp. New research from Newcastle University suggests a single 10-minute high-intensity cycling session can quickly change blood molecules, increasing 13 proteins including one tied to DNA repair, potentially helping suppress cancer growth in overweight but otherwise healthy adults aged 50–78. In England, Mark and Carol spent three decades and tens of thousands restoring a closed 1950 train station into “The Old Station,” now open for visits and overnight stays. In the Mediterranean, Cyprus is fighting invasive lionfish by serving it in restaurants. British veteran Hari became the first above-the-knee double amputee to climb the highest mountain on every continent.John also hosts Daily Comedy NewsUnlock an ad-free podcast experience with Caloroga Shark Media!  For Apple users, hit the banner which says Uninterrupted Listening on your Apple podcasts app. Subscribe now for exclusive shows like 'Palace Intrigue,' and get bonus content from Deep Crown (our exclusive Palace Insider!) Or get 'Daily Comedy News,' and '5 Good News Stories' with no commercials! Plans start at $4.99 per month, or save 20% with a yearly plan at $49.99. Join today and help support the show!Get more info from Caloroga Shark Media and if you have any comments, suggestions, or just want to get in touch our email is info@caloroga.com

In this episode of the Dementia Research Podcast, host Dr Gemma Lace is joined by guests, Dr Eric Hill from Loughborough University, Kalliopi Mavromati from University of Glasgow, Natalie Wickett from Simon Fraser University and Dr Kate Harris from Newcastle University. Together they discuss the intersection of ADHD and research, exploring personal experiences, misconceptions, and coping strategies. The conversation highlights the unique challenges faced by researchers with ADHD, the importance of understanding and empathy in academic settings, and the various ways individuals navigate their symptoms. The discussion also touches on the role of medication and the need for tailored approaches to support neurodiverse individuals in academia. -- A transcript of this show, links and show notes and profile on all our guests are available on our website at https://www.dementiaresearcher.nihr.ac.uk -- Follow us on social media: https://www.instagram.com/dementia_researcher/ https://www.facebook.com/Dementia.Researcher/ https://www.twitter.com/demrescommunity https://www.linkedin.com/company/dementia-researcher https://www.bsky.app/profile/dementiare…archer.bsky.social -- Download and Register with our Community App: https://www.onelink.to/dementiaresearcher -- Chapters 00:00 Introduction to ADHD in Research 02:56 Understanding ADHD: Definitions and Misconceptions 06:55 Personal Experiences of ADHD 10:37 Hyperfocus: The Double-Edged Sword 14:22 Gender Differences in ADHD Presentation 21:46 ADHD in Academia: Challenges and Realizations 25:35 The Positive Aspects of ADHD 29:11 Coping Mechanisms and Strategies 34:10 Medication: The Good, The Bad, and The Necessary 48:14 Final Thoughts and Key Takeaways

On this edition of The Media Show, Ros Atkins examines the continuing public interest in the Lucy Letby case, as a new Netflix documentary reaches the top of the UK viewing rankings. He speaks to Josh Halliday, North of England Editor at The Guardian, and Dr Bethany Usher of Newcastle University, whose work focuses on the ethics of true‑crime storytelling and the development of new guidelines for the genre.Tom Freston, co‑founder of MTV, reflects on how the channel's launch in 1981 transformed popular culture and what its closure in the UK and Europe signifies for its legacy.And we assess the state of the advertising industry following one of its most challenging years on record. James Kirkham, founder of Iconic, discusses his view that the traditional agency model is in steep decline, while Becky Owen, Chief Marketing Officer at Billion Dollar Boy, outlines the rapid expansion of influencer marketing and the new dynamics shaping the sector.Producer: Lisa Jenkinson

Max Pearson presents a collection of the week's Witness History interviews from the BBC World Service.We travel back to Chile in 2006 where more than 600,000 schoolchildren are marching through the streets to protest about their schools. The nationwide demonstrations will become known as the "Penguin Revolution".Our guest Dr Laura Tisdall, a historian from Newcastle University, explains why this isn't the first time children have challenged authority.And we examine another protest in Kaohsiung, Taiwan, in 1979 which became a seminal moment in the country's transition to democracy.Plus, one of the most defining moments of World War Two – the liberation of Auschwitz, the Nazis' largest death camp in 1945.And the remarkable story of the 5,000-year-old mummy found frozen and perfectly preserved in Europe's Ötzal Alps in 1991. In sport, we explore the inspiring story of how rugby union came to thrive in Syria - despite mass protests and violent government crackdowns during 2011...Finally, we celebrate 100 years since a technological breakthrough that would change the world. The start of television.Contributors:Karina Delfino – one of the leaders of the Penguin Revolution.Dr Laura Tisdall - lecturer in Modern British History, Newcastle University.Yao Chia-wen – protester in the Kaohsiung Incident.General Vasily Petrenko – Soviet army commander who helped liberate Auschwitz. Konrad Spindler – archaeologist.Rainer Henn - forensic pathologist.Mohamad Jarkou – Syrian rugby union player.Iain Logie Baird – grandson of John Logie Baird, the inventor of television.(Photo: High school students in Santiago, 2006. Credit: Claudio Pozo/AFP via Getty Images)

Our contemporary world is inescapably Greek. Whether in a word like “pandemic,” a Freudian state of mind like the “Oedipus complex,” or a replica of the Parthenon in a Chinese theme park, ancient Greek culture shapes the contours of our lives. Ever since the first Roman imitators, we have been continually falling under the Greeks' spell. But how did ancient Greece spread its influence so far and wide? And how has this influence changed us? In What the Greeks Did for Us (Yale UP, 2023), Tony Spawforth explores our classical heritage, wherever it's to be found. He reveals its legacy in everything from religion to popular culture, and unearths the darker side of Greek influence—from the Nazis' obsession with Spartan “racial purity” to the elitism of classical education. Paying attention to the huge breadth and variety of Hellenic influence, this book paints an essential portrait of the ancient world's living legacy—considering to whom it matters, and why. Tony Spawforth is emeritus professor of ancient history at Newcastle University. As well as leading cultural tours in Greece, he has presented eight documentaries for the BBC and has published thirteen books, including The Story of Greece and Rome. Morteza Hajizadeh is a Ph.D. graduate in English from the University of Auckland in New Zealand. His research interests are Cultural Studies; Critical Theory; Environmental History; Medieval (Intellectual) History; Gothic Studies; 18th and 19th Century British Literature. YouTube channel. Twitter. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/intellectual-history

Noninterventional studies in clinical research are underutilized in clinical research and inefficient. Dan Drozd, CMO of PicnicHealth, knows we can do better. With host Deborah Borfitz, Drozd discusses the issues and ramifications researchers face from the lack of noninterventional studies, offers tactics for raising the bar for evidence generation, and shares what he expects in the clinical research space in 2026 in this episode of the Scope of Things. Plus, Borfitz shares the latest news on an expanding good pharma score card, an entirely telehealth-based cancer trial, a novel online platform for bowel cancer research, improving patient-reported outcomes in cancer trials, a virtual clinical trial for psychedelics, and identifying Type 1 diabetes in the symptom-less window stage. Show Notes   News Roundup Good Pharma Scorecard Study in JAMA Internal Medicine News on the Yale Scool of Medicine website  Nationwide telehealth trial for cancer News on The Ohio State University website Online platform for bowel cancer research News on the Newcastle University website Patient-reported outcomes in cancer clinical trials Paper in The Lancet Oncology News on the European Organisation for Research and Treatment of Cancer website Virtual clinical trial of psychedelics Research article in Advanced Science Type 1 diabetes risk prediction testing Study in The Lancet News on the University of Exeter website Guest Dan Drozd, M.D., CMO of PicnicHealth The Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News senior writer, Deborah Borfitz, welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider's look at clinical research today.

Our contemporary world is inescapably Greek. Whether in a word like “pandemic,” a Freudian state of mind like the “Oedipus complex,” or a replica of the Parthenon in a Chinese theme park, ancient Greek culture shapes the contours of our lives. Ever since the first Roman imitators, we have been continually falling under the Greeks' spell. But how did ancient Greece spread its influence so far and wide? And how has this influence changed us? In What the Greeks Did for Us (Yale UP, 2023), Tony Spawforth explores our classical heritage, wherever it's to be found. He reveals its legacy in everything from religion to popular culture, and unearths the darker side of Greek influence—from the Nazis' obsession with Spartan “racial purity” to the elitism of classical education. Paying attention to the huge breadth and variety of Hellenic influence, this book paints an essential portrait of the ancient world's living legacy—considering to whom it matters, and why. Tony Spawforth is emeritus professor of ancient history at Newcastle University. As well as leading cultural tours in Greece, he has presented eight documentaries for the BBC and has published thirteen books, including The Story of Greece and Rome. Morteza Hajizadeh is a Ph.D. graduate in English from the University of Auckland in New Zealand. His research interests are Cultural Studies; Critical Theory; Environmental History; Medieval (Intellectual) History; Gothic Studies; 18th and 19th Century British Literature. YouTube channel. Twitter. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

Our contemporary world is inescapably Greek. Whether in a word like “pandemic,” a Freudian state of mind like the “Oedipus complex,” or a replica of the Parthenon in a Chinese theme park, ancient Greek culture shapes the contours of our lives. Ever since the first Roman imitators, we have been continually falling under the Greeks' spell. But how did ancient Greece spread its influence so far and wide? And how has this influence changed us? In What the Greeks Did for Us (Yale UP, 2023), Tony Spawforth explores our classical heritage, wherever it's to be found. He reveals its legacy in everything from religion to popular culture, and unearths the darker side of Greek influence—from the Nazis' obsession with Spartan “racial purity” to the elitism of classical education. Paying attention to the huge breadth and variety of Hellenic influence, this book paints an essential portrait of the ancient world's living legacy—considering to whom it matters, and why. Tony Spawforth is emeritus professor of ancient history at Newcastle University. As well as leading cultural tours in Greece, he has presented eight documentaries for the BBC and has published thirteen books, including The Story of Greece and Rome. Morteza Hajizadeh is a Ph.D. graduate in English from the University of Auckland in New Zealand. His research interests are Cultural Studies; Critical Theory; Environmental History; Medieval (Intellectual) History; Gothic Studies; 18th and 19th Century British Literature. YouTube channel. Twitter. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/literary-studies

Taylor Swift's Eras Tour shattered records, becoming the highest-grossing concert tour of all time, redefining what's possible and confirming a new era in the business of touring. As streaming transformed how we listen to music, selling records is no longer the financial centrepiece it once was for artists. Instead, exclusivity has been transferred to the live experience. But staging shows on this scale requires enormous investment and complex production. At the same time, ticket scarcity fuels extraordinary demand and rising prices, which mean big ticket prices.Tanya Beckett explores how technology, fandom and economics turn modern concert tours into multi-billion-dollar ventures.This week on The Inquiry, we're asking: How did music megatours become such a money spinner?Contributors Kevin Kim, Head of Asia at music distribution company Route Note, Seoul, South KoreaSerona Elton, professor at the Frost School of Music at the University of Miami, United StatesAdam Behr, Reader and Head of Music at Newcastle University, United KingdomPoppy Reid, music journalist and founder of Curious Media, Sydney, AustraliaPresenter: Tanya Beckett Producers: Maeve Schaffer and Matt Toulson Researcher: Evie Yabsley Production Management Assistant: Liam Morrey Technical Producer: Craig Boardman Editor: Tom Bigwood(Photo: Taylor Swift during The Eras Tour. Credit: Erika Goldring/TAS24/Getty Images)

In this episode, Amina Easat Daas and Claudia Radiven were in conversation with Peter Hopkins to discuss his work and most recent book, Everyday Islamophobia. The conversation ranged from UK counter-terror policy, to citizenship, the Far-Right, but largely on the mainstreaming of Islamophobia. Peter Hopkins is a Professor of Social Geography in the School of Geography, Politics and Sociology at Newcastle University. His interests centre upon issues of social inequality and justice with most of his research focusing upon the intersections of youth, migration and asylum, race and religion, and gender. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

Checkpoint 300, the highly securitized border facility between occupied Bethlehem and Jerusalem, is a central feature of Israeli control of Palestinian land and life. An apparatus of turnstiles, overcrowded corridors, and invasive inspections, the checkpoint regulates the movement of hundreds of thousands of Palestinians, granting access to some while excluding most. Offering a nuanced exploration of space in Checkpoint 300: Colonial Space in Palestine (U Minnesota Press, 2025), Mark Griffiths reveals Checkpoint 300 as a stark symbol of Israeli colonialism that embodies larger systems of control and violence. Griffiths's sensitive and timely work highlights the myriad ways Palestinians are affected by Israel's spatial control—whether they travel through the checkpoint or not—demonstrating how colonial infrastructures of inequity extend far beyond their physical boundaries to shape daily life. Drawing on nearly a decade of fieldwork, Griffiths examines how colonial power infiltrates family dynamics, enforces gendered mobility restrictions, shapes local economies, and extends into the global exchange of capital and security technologies. He also underscores how Palestinians endure and resist under oppressive conditions and how indigenous forms of life and living are sustained, illuminating how colonial space is contested and countered, unmade and remade. Blending meticulous research with vivid human stories to show the lived realities of borders, power, and resistance in the West Bank, Checkpoint 300 portrays the checkpoint as an entry into the ways that colonial space is formed through security infrastructure that is both the product and producer of wider geographies of oppression, complicity, and control. Mark Griffiths is reader in political geography at Newcastle University. He is coeditor of Encountering Palestine: Un/making Spaces of Colonial Violence. Morteza Hajizadeh is a Ph.D. graduate in English from the University of Auckland in New Zealand. His research interests are Cultural Studies; Critical Theory; Environmental History; Medieval (Intellectual) History; Gothic Studies; 18th and 19th Century British Literature. YouTube channel. Twitter. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

Host Jason Blitman talks to award-winning Irish writer Gráinne O'Hare about her debut novel, Thirst Trap. Conversation highlights include:❤️‍